CLSP derivatives not affected by CLSP-inhibiting substances and enhancers / protectants for CLSP activity

By designing CLSP derivatives and adiponectin derivatives with specific amino acid sequences, the activity of CLSP was enhanced and protected from inhibition by hindering substances, thus solving the problem of reduced CLSP activity in Alzheimer's disease patients. This achieved the therapeutic effect of effectively enhancing CLSP activity at low concentrations and overcoming the blood-brain barrier in AD treatment.

CN114531877BActive Publication Date: 2024-11-15TOKYO MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202080057660.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-08-15
Filing Date
2020-07-17
Publication Date
2024-11-15
Estimated Expiration
2040-07-17

AI Technical Summary

Technical Problem

In the existing technology, CLSP has reduced activity in the central nervous system of Alzheimer's patients, and it is difficult to effectively enhance its activity through peripheral administration. The blood-brain barrier also makes it difficult for the drug to enter the CNS.

Method used

CLSP derivatives and adiponectin derivatives were developed. By designing specific amino acid sequences, CLSP activity was enhanced and protected from inhibition by barrier substances. The activity was enhanced by the binding of adiponectin to CLSP. Furthermore, fusion proteins were designed to make them more easily cross the blood-brain barrier.

Benefits of technology

It effectively enhances CLSP activity at low concentrations, overcomes the blood-brain barrier, provides an effective treatment for AD, reduces side effects, and improves drug penetration in the CNS.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114531877B_ABST
    Figure CN114531877B_ABST
Patent Text Reader

Abstract

The present invention provides: a derivative of calmodulin-like skin protein (CLSP), which has a stronger activity than human peptides in inhibiting the dysfunction or cell death of nerve cells associated with Alzheimer's disease, and is not inhibited by inhibitors; and a polypeptide, etc., which has an enhancing or protective effect / activity on the inhibitory activity of CLSP against Alzheimer's disease. A mutant, characterized in that it is a derivative (mutant) of calmodulin-like skin protein (CLSP), comprising an endogenous human peptide homology region (EHR) as the center of the activity (CLSP activity) for inhibiting the dysfunction or cell death of nerve cells associated with Alzheimer's disease, and does not contain the region to which the CLSP activity inhibitor binds; a pharmaceutical composition, etc., comprising the mutant as an active ingredient, for inhibiting the dysfunction or cell death of nerve cells associated with Alzheimer's disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to: a derivative of calmodulin-like skin protein (CLSP), which has the activity of inhibiting the dysfunction of nerve cells or the death of nerve cells associated with Alzheimer's disease (AD), and is not inhibited or inhibited by an inhibitory substance (inhibitor); an enhancer or protector of the activity of CLSP (also referred to as "AD protective activity", "anti-AD activity", "CLSP activity" or "cytotoxicity inhibitory activity of CLSP"), which is composed of a polypeptide containing a collagen homology region of adiponectin; a fusion protein containing CLSP or the CLSP derivative and the polypeptide; and a pharmaceutical composition containing them as an active ingredient, in particular a pharmaceutical composition for treating Alzheimer's disease. Background Art

[0002] Alzheimer's disease (AD) is a major neurodegenerative disease that causes dementia. The etiology of AD has not yet been fully elucidated, and disease-modifying (disease prevention and progression inhibition) therapies for AD are still far from being practical (1-3).

[0003] Humanin and CLSP, physiologically active peptides, are physiological agonists for the heterotrimeric human peptide receptor (htHNR) composed of ciliary neurotrophic factor receptor α, WSX-1 and gp130 (4-6). They inhibit AD-related neuronal cell death in vitro via htHNR (5, 7). In addition, transgenic overexpression of CLSP protects it from synaptic loss and memory loss in AD model mice (8). However, the activity of humanin is weak (50% effective concentration is 1 to 10 μM) (6, 7), and it is believed that the concentration of humanin present in vivo is insufficient to exert a neuroprotective effect (6, 9).

[0004] CLSP is mainly produced in skin keratinocytes, and a small amount is also produced in epithelial cells of some peripheral tissues (10-12). Scopolamine-induced memory impairment in mice was improved by intraperitoneal administration of CLSP (13). In addition, sufficient amounts of CLSP are present in human cerebrospinal fluid (14). These experimental facts suggest that CLSP is transported from peripheral tissues through the blood circulation to the central nervous system (CNS), and then enters the nervous tissue through the blood-brain barrier (14). The sequence consisting of 22 amino acids at positions 40 to 61 in CLSP, namely HER (endogenous human peptide homology region), is indispensable for CLSP activity (5), and the activity of wild-type CLSP is 10 times stronger than that of human peptide. 5times (50% effective concentration is 10-100pM) (5). In addition, based on the measured concentration of CLSP in human cerebrospinal fluid (14), it is speculated that the concentration of CLSP in the CNS is sufficient to show a neuroprotective effect as an AD protective factor. Based on these published insights (5, 6, 8, 9, 13 and 14), the core agonist of htHNR in the body is likely to be CLSP rather than human peptides. In addition, according to previous studies (35), it is suggested that the activation level of htHNR is reduced in the CNS of AD patients. Therefore, as a further inference, it is proposed that the level of CLSP, which is the core agonist of htHNR, may be reduced in the CNS of AD patients. However, according to the recent study of the present inventors (14), the possibility that the CLSP level itself is reduced in the CNS of AD patients is denied.

[0005] Human peptides and CLSP, and their actions and effects are described in detail in Patent Document 1 in addition to the references cited by numbers above.

[0006] On the other hand, adiponectin is a peptide hormone derived from adipose tissue, which binds to receptors such as adiponectin R1 and adiponectin R2 to activate intracellular signals mediated by AMP kinase, thereby showing various metabolic effects such as increasing insulin sensitivity, insulin-independent glucose uptake, and decomposition of fatty acids. The results suggest that the hormone plays a role in inhibiting type II diabetes, obesity, atherosclerosis, non-alcoholic fatty liver disease, metabolic syndrome, and related metabolic abnormalities.

[0007] As described below, indirect evidence that adiponectin deficiency or abnormal regulation of adiponectin signaling is associated with the pathogenesis of AD is shown in the form of preliminary data from multiple studies (31). Increased serum adiponectin levels (29, 30) may be an independent risk factor for AD (32). Conversely, studies have shown that AD-like conditions occur in type II diabetic patients with low serum adiponectin concentrations (33). Adiponectin levels are reduced in the CSF of AD patients and are inversely correlated with increased Aβ levels (30). Adiponectin knockout mice display AD-like symptoms and pathological findings (34).

[0008] Prior art literature

[0009] Patent Literature

[0010] Patent document 1: Japanese Patent No. 5939528. Summary of the invention

[0011] Research has shown that CLSP binds to a variety of proteins in addition to htHNR (15), but how these bindings affect CLSP function has not yet been clarified.

[0012] The first object of the present invention is to study the possibility that these CLSP binding factors and the CLSP binding factors newly discovered in the present invention regulate CLSP activity and to conduct a detailed mechanism analysis of the regulated proteins.

[0013] The second task is to confirm that CLSP activity is reduced in the central nervous system of AD using samples from AD patients and to study the possibility that abnormalities in these CLSP binding factors contribute to the pathogenesis of AD.

[0014] Furthermore, the third subject is to provide: CLSP derivatives that are not inhibited or suppressed by inhibitors on CLSP activity, enhancers or protectors of CLSP activity possessed by CLSP and the CLSP derivatives, fusion proteins of CLSP or the CLSP derivatives and enhancers or protectors, and pharmaceutical compositions containing them as active ingredients for inhibiting neuronal dysfunction or neuronal cell death associated with Alzheimer's disease, etc.

[0015] Means for solving problems

[0016] The present inventors have conducted intensive studies to solve the above-mentioned problems and have obtained the following findings for the first time in the technical field, thereby completing the present invention.

[0017] First, it was found that CLSP activity was inhibited by CLSP inhibitors (agents) such as apolipoprotein E (Apolipoprotein E: ApoE; ApoE3 and ApoE4 used in this experiment are homologous proteins with one amino acid difference and basically the same biochemical properties), 14-3-3 protein and calreticulin ( Figure 2 and Figure 3 ). A series of data confirmed that these CLSP inhibitory substances showed complete CLSP inhibitory effects at concentrations equal to to 5 times the CLSP concentration in the culture medium. It is known that ApoE exists in the human central nervous system at a concentration absolutely higher than the CLSP concentration. For example, the ApoE concentration in human cerebrospinal fluid (CSF) is estimated to be 40-200nM (18, 19), while the CLSP concentration is estimated to be 3-6nM (14). Therefore, if it is assumed that the CLSP activity in the CNS in vivo is regulated by a simple system consisting only of CLSP and its inhibitory substances, it is believed that the activity of CLSP is completely ineffective by such a high concentration of endogenous ApoE (in fact, in normal organisms, as described later, there are CLSP protective substances to maintain CLSP activity ( Figure 5 , Figure 6 , Figure 7Therefore, as a therapeutic method, in order to reflect the decreased CLSP activity in the central nervous system of AD by increasing the wild-type CLSP ( Fig.10 , 11 , Tables 1, 2, 3, and 4), the CLSP concentration in the CNS must be increased to at least 40-200 nM to overcome the obstruction of CLSP inhibitory substances. However, since CLSP cannot effectively penetrate the blood-brain barrier and enter the central nervous system (5, 14), this is difficult to achieve by administering wild-type CLSP from a peripheral route. For example, in mice, 1 hour after intraperitoneal injection of 5 nmol of wild-type CLSP (usually predicted to reach the maximum concentration), the CLSP concentrations in CSF and serum reached 5 nM and 500 nM, respectively (5). Therefore, according to simple calculations, in order to rise to a concentration of 40-200 nM or more in CSF, it is necessary to administer at least about 10 times more wild-type CLSP. However, the 5 nmol administered in the above experiment is already a very large amount for mice, and it is difficult to increase the dosage above it in reality. That is, it is almost impossible for CLSP activity to appear in the CNS by peripheral injection of wild-type CLSP. Therefore, in order to induce CLSP activity in the CNS by peripheral administration of CLSP, it is necessary to make changes or designs such that CLSP can more efficiently permeate the blood-brain barrier and / or release CLSP from the inhibitory effect of CLSP inhibitory substances.

[0018] The present inventors found that ApoE4 binds to CLSP via the C-terminal region (amino acids 62-146) of CLSP. Fig. 9 and Supplementary Figure S4). This insight shows that the N-terminal region of CLSP (amino acids 1-61: referred to as "CLSP1-61") does not bind to ApoE and is not inhibited by ApoE. Importantly, the inventors further demonstrated that CLSP1-61 has the same activity as wild-type CLSP in inhibiting V642I-APP-induced neuronal cell death (Figure L1). In fact, the minimum required concentration of CLSP1-61 produced in E. coli and wild-type CLSP to completely block V642I-APP-induced neuronal cell death is 0.5 nM (Figures L1 and Figure 2 ).

[0019] As expected, the inhibition of V642I-APP-induced neuronal cell death mediated by CLSP1-61 was not inhibited by ApoE3, nor by other CLSP inhibitors such as 14-3-3σ protein or calreticulin (Figure L2). The above confirmed that CLSP1-61 was completely liberated from the inhibition of CLSP inhibitors and its activity was almost the same as that of the wild type, so it is a CLSP derivative that exhibits CLSP activity in vivo at a concentration far lower than that of the wild type CLSP.

[0020] [SEQ ID NO:1CLSP(1-146)]

[0021] mageltpeeeaqykkafsavdtdgngtinaqelgaalkatgknlseaqlrklisevdsdgdgeisfqefltaakkaragledlqvafrafdqd gdghitvdelrramaglgqplpqeeldamireadvdqdgrvnyeefarmlaqe (Depending on genetic polymorphism, the s at position 58 is sometimes a g, but the activity is the same)

[0022] It was further found that adiponectin binds to the HER (endogenous human peptide homology region) of CLSP ( Figure 1 and Fig. 9 , Fig. S4 ), enhancing CLSP activity (activity enhancer; Figure 7 ), and protect (maintain) CLSP activity from all kinds of CLSP-inhibiting substances (activity protection factor; Figure 5 , Figure 6 In fact, even in the presence of an absolutely high concentration of CLSP-blocking substances up to 50 nM, AD-related cell death was completely inhibited by 1 nM CLSP if adiponectin was present at a concentration of 0.2-0.25 nM ( Figure 5 and Figure 7 ). This result shows that adiponectin is a CLSP activity protective factor that maintains the activity of CLSP in the CNS where CLSP inhibitory substances exist at a concentration absolutely higher than that of CLSP.

[0023] It was further found that the level of adiponectin in CSF of AD patients was reduced to 0.3 nM ( Fig.10 , Tables 1 and 2). This result is consistent with previous studies (30). It was also found that the intensity of CLSP signals in neurons was reduced in AD patients ( Fig.11 , Tables 3 and 4). Taken together, these results suggest that in AD patients, adiponectin levels are somehow reduced in the CNS, resulting in reduced CLSP activity and neuronal sensitization to AD-related toxicity (i.e., neurotoxicity).

[0024] The present inventors also found that the collagen homology region of adiponectin (ADN) (ADNCol: equivalent to the amino acid sequence at positions 45 to 104 in AND) alone binds to CLSP (Figure S4) and is sufficient to show CLSP enhancing / protective activity (Figures L3 and L4). Importantly, the CLSP enhancing / protective activity of ADNCol is only slightly weaker than that of wild-type adiponectin. In fact, the minimum concentration of wild-type adiponectin for conferring complete CLSP enhancing / protective activity is 0.2-0.25 nM, while the minimum concentration of ADNCol is 0.5 nM. In addition, it is known that the globular domain located at the C-terminus of adiponectin is essential for the regulation of the metabolic activity of adiponectin, such as the glucose-lowering effect mediated by the common adiponectin receptors AdipoR1 and 2 (42). Therefore, ADNCol lacking the globular domain lacks these metabolic effects of adiponectin. That is, although ADNCol lacking the globular domain has the same complete CLSP activity enhancement / protection effect as wild-type ADN, it is different from wild-type AND and cannot bind to the common adiponectin receptor. As a result, it is believed that it does not show the so-called metabolic regulation activity (activity that may become a side effect). On the other hand, in previously published studies (33, 34), it was speculated that the anti-AD activity of adiponectin is mediated by the metabolic regulation activity caused by binding to the common adiponectin receptors AdipoR1 and 2.

[0025] Based on the above, it is predicted that ADNCol as a CLSP enhancer / protector has four advantages over wild-type adiponectin. First, considering the abundance of common adiponectin receptors AdipoR1 and 2 (common adiponectin receptors) in tissues (CNS or peripheral tissues) in vivo, it is speculated that a considerable proportion of wild-type adiponectin is consumed in forming a complex with the common adiponectin receptor, while this is not the case with ADNCol. Second, it is suggested that the reduction in CSF adiponectin levels in AD may be due to consumption due to the formation of an insoluble complex with hyperphosphorylated Tau in neurons (30), but it is speculated that this process is caused by the binding of wild-type adiponectin to the common adiponectin receptor and its uptake by neurons. Since ADNCol does not bind to the common adiponectin receptor, it is likely that it will not form a complex with hyperphosphorylated Tau in neurons. The above two points suggest that the amount of ADNCol required to show CLSP enhancing / protective activity in vivo is less than that of wild-type adiponectin. Third, a large amount of wild-type adiponectin may cause side effects by binding to the common adiponectin receptor and activating various metabolic pathways, but ADNCol does not bind to the common receptor, so it is presumed that there are no such side effects. Fourth, compared with the amino acid length of wild-type adiponectin (244 amino acids: SEQ ID NO: 3), the amino acid length of ADNCol (60 amino acids: SEQ ID NO: 2) is relatively short, so it is easy to produce industrially. Based on all the advantages of ADNCol mentioned above, ADNCol is also superior to wild-type adiponectin as an anti-AD drug.

[0026] In addition, the present inventors found that: CLSP or CLSP derivatives and enhancers or protective agents of the fusion protein (hybrid peptide) has a stronger protective activity than CLSP1-61 and wild-type CLSP against V642I-APP-induced neuronal cell death (Figure L5). That is, the minimum concentration of the hybrid peptide composed of CLSP1-61 and ADNCol (named "CLSPCOL") and the hybrid peptide composed of wild-type CLSP and ADNCol (named "wt-CLSPCOL") for completely inhibiting V642I-APP-induced neuronal cell death is 0.1nM, and the minimum concentration of CLSP1-61 and wild-type CLSP is 0.5nM (Figure L5). In addition, CLSPCOL and wt-CLSPCOL are not inhibited by CLSP inhibitors, and even if they are inhibited, the degree is mild (Figures X1 and X2).

[0027] It was further found that CLSPCOL more effectively permeated the blood-brain barrier and transferred to the CNS than wt-CLSPCOL (Figure L6 and Table 1). That is, 1 hour after intraperitoneal injection of 10 nmol of CLSPCOL in mice, the concentration of CLSPCOL in brain homogenate containing interstitial fluid (ISF) was 72 nM and in serum was 320 nM (Figure L6 and Table L1).

[0028] [ADNCol: SEQ ID NO: 2]

[0029] ghpghngapgrdgrdgtpgekgekgdpgligpkgdigetgvpgaegprgfpgiqgrkgep

[0030] [ADN: SEQ ID NO: 3]

[0031] mlllgavllllalpghdqetttqgpgvllplpkgactgwmagipghpghngapgrdgrdgtpgekgekgdpgligpkgdigetgvpgaeg

[0032] prgfpgiqgrkgepgegayvyrsafsvgletyvtipnmpirftkifynqqnhydgstgkfhcnipglyyfayhitvymkdvkvslfkkdk

[0033] amlftydqyqennvdqasgsvllhlevgdqvwlqvygegernglyadndndstftgfllyhdtn

[0034] That is, the present invention relates to the following aspects.

[0035] [Solution 1]

[0036] Calmodulin-like skin protein (CLSP) derivatives (mutants), wherein the derivatives are characterized by:

[0037] Contains an endogenous human peptide homology region (EHR), which is the center of activity (CLSP activity) that inhibits neuronal dysfunction or neuronal cell death associated with Alzheimer's disease.

[0038] The region to which the CLSP activity inhibitor binds is not included.

[0039] [Solution 2]

[0040] The derivative of Scheme 1, wherein HER is composed of the amino acid sequence (I):

[0041] TGKNLSEAQLRKLISEVDS (or G)DGD (single letter representation of amino acid) (I).

[0042] [Solution 3]

[0043] The derivative according to embodiment 1 or 2, wherein the region to which the inhibitor binds is the amino acid sequence (amino acids 62 to 146) of the C-terminal region of CLSP (SEQ ID NO: 1).

[0044] [Solution 4]

[0045] The derivative according to any one of Schemes 1 to 3, which is a polypeptide consisting of the following amino acid sequence:

[0046] (1) Amino acid sequence of the N-terminal region of CLSP (amino acids 1 to 61);

[0047] (2) an amino acid sequence in the amino acid sequence of (1) above, in which one or more (e.g., about 2 to 5) amino acids are deleted, substituted or inserted in an amino acid sequence other than EHR contained in the amino acid sequence; or

[0048] (3) An amino acid sequence of the above-mentioned (1) that has 90% or more, preferably 95% or more, and more preferably 98% or more identity with an amino acid sequence other than EHR contained in the amino acid sequence.

[0049] [Solution 5]

[0050] The derivative according to any one of Schemes 1 to 4, wherein the derivative is not inhibited or suppressed by an inhibitor on CLSP activity.

[0051] [Solution 6]

[0052] The derivative according to any one of embodiments 1 to 5, wherein the inhibitor is selected from the group consisting of apolipoprotein E, 14-3-3 protein and calreticulin.

[0053] [Solution 7]

[0054] A polypeptide consisting of the following amino acid sequence:

[0055] (1) the amino acid sequence shown in SEQ ID NO: 2 (ADNCol);

[0056] (2) an amino acid sequence comprising the amino acid sequence (ADNCol) of (1) above;

[0057] (3) an amino acid sequence in which one or more amino acids are deleted, substituted or inserted in an amino acid sequence other than ADNCol contained in the amino acid sequence of adiponectin as shown in SEQ ID NO:3; or

[0058] (4) An amino acid sequence having 90% or more identity with an amino acid sequence other than ADNCol contained in the amino acid sequence of adiponectin shown in SEQ ID NO: 3.

[0059] [Scheme 8]

[0060] An enhancer or protector of the CLSP activity possessed by CLSP or the CLSP derivative described in Scheme 1, which is composed of the polypeptide described in Scheme 7.

[0061] [Solution 9]

[0062] The enhancing or protecting agent described in Scheme 8 is characterized in that it protects the CLSP from the hindering or inhibiting effect of the inhibitor on the activity of the CLSP, or renders the effect of the inhibitor ineffective.

[0063] [Scheme 10]

[0064] The enhancing or protecting agent according to embodiment 8 or 9, wherein the polypeptide is adiponectin.

[0065] [Scheme 11]

[0066] The enhancing or protecting agent according to any one of embodiments 8 to 10, wherein the inhibitor is selected from the group consisting of apolipoprotein E, 14-3-3 protein and calreticulin.

[0067] [Scheme 12]

[0068] A fusion protein comprising CLSP or the CLSP derivative described in Scheme 1 and the polypeptide described in Scheme 7.

[0069] [Scheme 13]

[0070] The fusion protein according to Scheme 12 is composed of the amino acid sequence (amino acids 1 to 61) of the N-terminal region of CLSP and ADNCol.

[0071] [Scheme 14]

[0072] The fusion protein described in Scheme 12 or 13 is not inhibited or suppressed by the inhibitory effect on CLSP activity.

[0073] [Scheme 15]

[0074] A pharmaceutical composition for inhibiting neuronal dysfunction or neuronal cell death associated with Alzheimer's disease, comprising the CLSP derivative of any one of Schemes 1 to 6, the polypeptide of Scheme 7, the enhancing or protecting agent of any one of Schemes 8 to 11, or the fusion protein of any one of Schemes 12 to 14 as an active ingredient.

[0075] [Scheme 16]

[0076] The pharmaceutical composition of embodiment 15 is used for preventing or treating diseases accompanied by memory impairment or neurodegeneration associated with Alzheimer's disease.

[0077] [Scheme 17]

[0078] A method for treating a disease accompanied by neuronal dysfunction or neuronal cell death, or a disorder accompanied by memory impairment or neurodegeneration, comprising: administering the pharmaceutical composition of scheme 15 or 16 to an individual suffering from or suspected of suffering from the disease or disorder.

[0079] [Scheme 18]

[0080] The method of claim 17, wherein the disease or condition is Alzheimer's disease.

[0081] [Scheme 19]

[0082] A method for detecting the inhibitory activity of the CLSP derivative of any one of Schemes 1 to 6, the polypeptide of Scheme 7, the enhancing or protecting agent of any one of Schemes 8 to 11, or the fusion protein of any one of Schemes 12 to 14 (collectively referred to as "the polypeptide of the present invention") on neuronal dysfunction or neuronal cell death associated with Alzheimer's disease, the method comprising: step (a), inducing neuronal dysfunction or neuronal cell death in the presence / absence of a CLSP inhibitor and in the presence / absence of the polypeptide of the present invention; step (b), detecting neuronal dysfunction or neuronal cell death; and step (c), comparing neuronal dysfunction or neuronal cell death in the presence / absence of the polypeptide of the present invention.

[0083] [Scheme 20]

[0084] A method for screening a substance that modulates the inhibitory activity of the CLSP derivative of any one of Schemes 1 to 6, the polypeptide of Scheme 7, the enhancing or protecting agent of any one of Schemes 8 to 11, or the fusion protein of any one of Schemes 12 to 14 (collectively referred to as "polypeptides of the present invention") or CLSP on neuronal dysfunction or neuronal cell death associated with Alzheimer's disease, the method comprising:

[0085] Step (a), inducing neuronal dysfunction or neuronal cell death in the presence of the polypeptide of the present invention or CLSP and in the presence or absence of a test substance; step (b), detecting neuronal dysfunction or neuronal cell death; and step (c), selecting a substance that modulates the inhibitory activity of the polypeptide of the present invention or CLSP on neuronal dysfunction or neuronal cell death.

[0086] Effects of the Invention

[0087] The CLSP derivatives of the present invention contain an endogenous human peptide homology region (EHR), which is an active (CLSP activity) center for inhibiting neuronal dysfunction or neuronal cell death associated with Alzheimer's disease, and do not contain a region to which CLSP activity inhibitors such as ApoE, 14-3-3σ protein or calreticulin bind.

[0088] As a result, the CLSP derivatives have the same degree of CLSP activity as the wild-type CLSP, and are substantially (significantly) not inhibited or inhibited by the inhibitor on the CLSP activity. The above shows that these polypeptides are completely freed from the inhibition / inhibition of the CLSP inhibitor and exhibit CLSP activity in vivo at a concentration far lower than that of the wild-type CLSP.

[0089] On the other hand, a polypeptide consisting of the amino acid sequence shown in SEQ ID NO:2 and serving as a collagen homology region of adiponectin, and a polypeptide comprising the amino acid sequence shown in SEQ ID NO:2, such as a trimer or other multimeric adiponectin, binds to the EHR located within CLSP and CLSP1-61 of the CLSP derivative of the present invention, and has the action / effect of enhancing the CLSP activity they possess.

[0090] Moreover, the polypeptide has the following action / effect: protecting CLSP from the inhibition or suppression of CLSP activity by inhibitors such as apolipoprotein E, or rendering the inhibitory or suppressive action of the inhibitor ineffective. Therefore, the polypeptide can be used as an enhancer or protective agent for suppressing the functional impairment or death of neural cells associated with Alzheimer's disease.

[0091] In addition, the fusion protein of the present invention has stronger anti-AD activity than the derivative composed of CLSP or a part of CLSP. In addition, the fusion protein is not hindered by the CLSP inhibitor, or even if it is hindered, it is at a very mild level. It is further predicted that the peptide lacks the metabolic-related activity from adiponectin and will not be consumed by forming a complex with the standard adiponectin receptor. In addition to these advantages, CLSPCOL, as one of the fusion proteins, also has the characteristic of excellent blood-brain barrier migration, so it is likely to become an ideal anti-AD drug that can be peripherally administered. BRIEF DESCRIPTION OF THE DRAWINGS

[0092] [ Figure 1 ]<Apolipoprotein E3, E4 and adiponectin binding to CLSP> Apolipoprotein E3, E4, adiponectin and annexin II tagged with HA at the C-terminus were overexpressed in F11 neural hybrid cells by transfection. 24 hours after transfection, F11 cells were recovered and cell lysates were prepared. Sepharose (agarose gel) 4B adjusted separately and bound to an appropriate amount of GST-MycHis or CLSP-MycHis was added to 300μg of the lysate, incubated overnight at 4°C, washed thoroughly, and then subjected to pull-down sedimentation (precipitation). The input consisting of cell lysate or Sepharose 4B beads bound to GST-MycHis (GST-MH) and CLSP-MycHis (CLSP-MH), and the pull-down sedimentation of the cell lysate were developed by SDS-PAGE, and then immunoblot analysis was performed using HA (hemagglutinin A) and myc antibodies.

[0093] [ Figure 2]<Apolipoprotein E3 and E4 inhibit CLSP activity> (a) For SH-SY5Y cells, pcDNA3.1 / MycHis vector (vector) or pcDNA3.2 / MycHis-V642I-APP (V642I-APP) was transfected. Then, culture was performed in DMEM / F12-10% FBS containing CLSP-MycHis at the indicated concentrations. 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing N2 supplement containing the same concentration of CLSP-MycHis. 48 hours after the start of transfection, cell survival assay using WST-8 cell death assay kit, or calcein AM staining, and trypan blue exclusion cell death assay were performed. In addition, cell lysates were subjected to immunoblot analysis using APP antibody 22C11. (b, c) For SH-SY5Y cells, pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) was transfected. Then, cells were cultured in DMEM / F12-10% FBS containing / without the indicated concentrations of BSA, apolipoprotein E3 (b) or E4 (c) and containing 1 nM of GST-MycHis or CLSP-MycHis. 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing / without the same concentrations of BSA, apolipoprotein E3 (b) or E4 (c) and containing N2 supplement containing 1 nM of GST-MycHis or GST-MycHis. Cells were collected 48 hours after the start of transfection and a trypan blue exclusion cell death assay was performed. In addition, cell lysates were subjected to immunoblot analysis using the APP antibody 22C11.

[0094] [ Figure 3]<14-3-3 family proteins and secretory calreticulin inhibit CLSP activity> (ae) For SH-SY5Y cells, pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) was transfected. Then, the cells were cultured in DMEM / F12-10% FBS containing / without the indicated concentrations of BSA and 14-3-3 isoforms and containing 10 nM of GST-MycHis or CLSP-MycHis. 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing / without the same concentration of BSA or 14-3-3 isoforms and containing N2 supplement containing 10 nM of GST-MycHis or CLSP-MycHis. Cells were collected 48 hours after the start of transfection and a trypan blue exclusion cell death assay was performed. (f) SH-SY5Y cells were transfected with an empty pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP). Cells were then cultured in DMEM / F12-10% FBS containing / without 10 nM BSA, calreticulin, annexin II or annexin V and containing 10 nM GST-MycHis or CLSP-MycHis. 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing / without 10 nM BSA, calreticulin, annexin II or annexin V and containing N2 supplement containing the same concentration of GST-MycHis or CLSP-MycHis. Cells were harvested 48 hours after the start of transfection and a trypan blue exclusion cell death assay was performed. Cell lysates were immunoblotted using the APP antibody 22C11.

[0095] [ Figure 4 ]<Adiponectin protects CLSP activity from being hindered by apolipoprotein E3> (ac) SH-SY5Y cells were transfected with an empty pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP). Then, cells were cultured in DMEM / F12-10% FBS containing / without 10 nM adiponectin (a), annexin II (b) or annexin V (c) and containing 1 nM GST-MycHis or CLSP-MycHis. 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing N2 supplement containing the same combination of proteins. Trypan blue exclusion cell death assay was performed 48 hours after the start of transfection. In addition, cell lysates were subjected to immunoblot analysis using APP antibody 22C11.

[0096] [ Figure 5]<Adiponectin protects CLSP activity from being blocked by apolipoprotein E4> (a) For SH-SY5Y cells, pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP / MycHis-V642I-APP (V642I-APP) was transfected. Then, the cells were cultured in DMEM / F12-10% FBS containing / without adiponectin at the indicated concentrations, containing / without 10 nM apolipoprotein E4, and containing 1 nM GST-MycHis or CLSP-MycHis. 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing N2 supplement containing the same combination of proteins. The cells were recovered 48 hours after the start of transfection, and WST-8 and trypan blue exclusion cell death assays were performed. The cell lysates were subjected to immunoblot analysis using APP antibody 22C11. (b) pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) was transfected into SH-SY5Y cells. The cells were then cultured in DMEM / F12-10% FBS containing / without 1 nM adiponectin, containing / without apolipoprotein E4 at stepwise increasing concentrations, and containing 1 nM GST-MycHis or CLSP-MycHis. 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing N2 supplement containing the same combination of proteins. Cells were recovered 48 hours after the start of transfection and subjected to WST-8 and trypan blue exclusion cell death assays. Cell lysates were subjected to immunoblot analysis using APP antibody 22C11.

[0097] [ Figure 6 ]<Adiponectin protects CLSP from 14-3-3σ and calreticulin> (a, b) SH-SY5Y cells were transfected with pcDNA3 vector (vector) or pcDNA3-V642I-APP (V642I-APP). Then, cells were cultured in DMEM / F12-10% FBS containing / without 2nM 14-3-3σ (a) or 10nM calreticulin (b), containing / without 1nM adiponectin and containing 1nM GST-MycHis or CLSP-MycHis. 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing N2 supplement containing the same combination of proteins. Cells were recovered 48 hours after the start of transfection, and trypan blue exclusion of cell death and WST-8 assay were performed. Cell lysates were subjected to immunoblot analysis using APP antibody 22C11.

[0098] [ Figure 7]<Adiponectin enhances CLSP activity> (a) pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) was transfected into SH-SY5Y cells. Then, the cells were cultured in a culture medium containing / without 200 pM adiponectin in DMEM / F12-10% FBS containing GST-MycHis or CLSP-MycHis at the indicated concentrations. 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing N2 supplement containing the same combination of proteins. (b) pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) was transfected into SH-SY5Y cells. Next, cells were cultured in DMEM / F12-10% FBS with / without adiponectin at the indicated concentrations and with GST-MycHis or CLSP-MycHis at the indicated concentrations. 24 hours after transfection, the medium was exchanged for DMEM / F12 containing N2 supplement containing the same combination of proteins. Cells were harvested 48 hours after transfection and subjected to trypan blue exclusion of cell death and WST-8 assay. Cell lysates were subjected to immunoblot analysis using APP antibody 22C11.

[0099] [ Figure 8 ]<The dissociation constant of the binding of adiponectin to CLSP and the dissociation constant of the binding of apolipoprotein E4 to CLSP are similar> (a) The presence of adiponectin is limited to slightly inhibiting the binding between apolipoprotein E4 and CLSP. PBS containing Sepharose 4B bound to CLSP-MycHis was mixed with adiponectin, annexin II, any one or two of recombinant apolipoprotein E3 or E4, incubated overnight at 4°C and then washed thoroughly. The final estimated concentration of each recombinant protein in the assay was 1 nM. Then, pull-down was performed, and the resulting precipitate, as well as Sepharose 4B beads bound to CLSP-MycHis and each recombinant protein were used as input for SDS-PAGE development, which was then visualized by silver staining. (b) Scatchard analysis was performed to determine the dissociation constant. Each well of a 96-well plate coated with 20 pM recombinant apolipoprotein E4 or adiponectin was filled with CLSP-HiBiT at stepwise increasing concentrations and incubated at room temperature for 2 hours. TMX5 (Perkin Elmer) was used to perform chemiluminescence assays and estimate HiBiT activity. The experiment was performed with N=2, and the average data of the two wells (average) were used for further analysis. The average CLSP-HiBiT activity at zero concentration (background) was subtracted from each average CLSP-HiBiT activity (average) to obtain the actual CLSP-HiBiT activity (Del / MEAN) bound to adiponectin or apolipoprotein E4. Then, referring to the standard dose-response curve consisting of the CLSP-HiBiT concentration and the corresponding chemiluminescence intensity (i.e., CLSP-HiBiT activity), the concentration of CLSP-HiBit bound to apolipoprotein E4 or adiponectin was estimated (using Then, the free CLSP-HiBiT concentration (non-bound concentration) was calculated (expressed as <f>The dissociation constants were calculated by Scatchard analysis using Prism7 software.

[0100] [ Fig. 9 ]<Apolipoprotein E4 and adiponectin bind to different sites of CLSP> (a) A schematic diagram showing deletion mutants of CLSP. (b) Apolipoprotein E4 (ApoE4) and adiponectin (ADN) tagged with FLAG at the C-terminus were overexpressed in F11 neural hybrid cells by transfection. F11 cells were recovered 24 hours after transfection and cell lysates were prepared. 300 μg of cell lysate was used in immunoprecipitation of ApoE4-FLAG and ADN-FLAG using FLAG antibody. In addition, recombinant CLSP-MycHis (FL-MH) or CLSP deletion mutants with a MycHis tag at the C-terminus were produced in bacteria and purified. Then, these immunoprecipitates and recombinant proteins were used as inputs for SDS-PAGE development using myc antibodies and FLAG antibodies, and immunoblot analysis was performed. (c) The ApoE4-FLAG and ADN-FLAG immunoprecipitates prepared in (b) were mixed with purified recombinant CLSP-MycHis (FL-MH) or C-terminal MycHis-tagged CLSP deletion mutants, incubated overnight at 4°C, and then washed thoroughly. The pull-down precipitates were then developed by SDS-PAGE using myc antibodies and FLAG antibodies and analyzed by immunoblotting.

[0101] [ Fig.10 ]<Decrease in adiponectin in the CSF of AD patients> (a) The adiponectin concentration in the CSF obtained from AD patients and non-AD controls shown in Table 1 was measured using the adiponectin ELISA system. A standard dose-response curve was prepared by measuring the step-by-step increase in the concentration of recombinant adiponectin. (b) The CSF adiponectin concentrations in AD patients and non-AD controls were plotted as points (AD cases N=14, non-AD cases N=20). The mean ± SEM of adiponectin concentrations are also shown (AD, 0.31±0.13 nM; non-AD, 0.96±0.19 nM; unpaired T test, p=0.0065). (c) The CSF adiponectin concentrations in AD patients aged 81 to 88 years and non-AD controls were plotted as points (AD cases N=6, non-AD cases N=5). Also shown are the mean ± SEM of adiponectin concentrations (AD, 0.30 ± 0.07 nM; non-AD, 1.41 ± 0.16 nM; unpaired T-test, p < 0.0001).

[0102] [ Fig.11 Decreased SH3BP5 levels in neurons of the AD cortex (a) Outer pyramidal layers of the temporal or occipital lobes from 2 AD patients (65-year-old male; 79-year-old female) and ALS patients (66-year-old male; 79-year-old male) were immunostained with anti-SH3BP5 antibody. Immunodetection was performed according to the tyramide red method. Scale bar is 200 mm. (b) Example of quantification of the immunofluorescence intensity of cells. The cell area and the non-cell area surrounding the cell were surrounded by a marker, and the average immunofluorescence intensity (x) of the cell area and the average immunofluorescence intensity (y) of the non-cell area surrounding the cell were measured. Then, the relative average immunofluorescence intensity in neurons was calculated by (x - y), and the SH3BP5 expression level in one neuron was calculated by multiplying the neuron area by the x - y value. (c) As shown in Table 2, sections of the outer pyramidal layer of the temporal or occipital lobes from AD patients and amyotrophic lateral sclerosis (ALS) patients (including the sections shown in (a)) were immunostained with anti-SH3BP5 antibody. Immunodetection was performed according to the tyramide red method. As described in detail in "Materials and Methods", the immunofluorescence intensity was measured using Image J 1.37v. The relative intensities in AD patients and ALS patients were plotted as points (AD cases N = 7, ALS cases N = 6). The mean ± SEM of the immunofluorescence intensity is also shown (AD, 46564 ± 7737 arbitrary units; ALS, 79225 ± 10305 arbitrary units; unpaired T test, p = 0.0256). (d, e) As shown in Table 3, the SH3BP5 concentration in 20 μL of lysates obtained from the temporal cortex of AD patients and non-AD was measured using SH3BP5 ELISA. A standard dose-response curve was made by measuring recombinant SH3BP5 with increasing concentrations (d). The relative concentrations of SH3BP5 in AD patients and non-AD were plotted (N = 10 for each group) (e). The mean ± SD of the relative SH3BP5 levels is also shown (AD, 103.9 ± 9.0 arbitrary units; normal, 159.4 ± 16.5 arbitrary units; unpaired T test, p = 0.0084).

[0103] Fig.12 Figure S1 (Supplementary Figure 1 ​)<Adiponectin itself did not inhibit V642I-APP-induced neuronal cell death, nor did it inhibit the reduction of V642I-APP-induced neuronal cell death mediated by CLSP> pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) was transfected into SH-SY5Y cells. Next, the cells were cultured in DMEM / F12-10% FBS containing / without adiponectin at stepwise increasing concentrations and containing GST-MH or CLSP-MH. 24 hours after transfection, the culture medium was exchanged with DMEM / F12 containing / without adiponectin at stepwise increasing concentrations and containing N2 supplement containing GST-MH or CLSP-MH. The cells were recovered 48 hours after the start of transfection, and cell survival assays were performed using WST-8 cell death assay kit (Dojindo, Kumamoto, Japan) or calcein AM staining (Dojindo) and trypan blue exclusion cell death assays. Additionally, cell lysates were subjected to immunoblot analysis using the APP antibody 22C11.

[0104] [ Fig.13 ] Figure S2 (Supplementary Figure 2 )<14-3-3σ levels in human CSF are below the detection limit> (a) The 14-3-3σ concentration in 20μL CSF obtained from 8 non-AD patients (CSF#1-8) was measured using the 14-3-3σ ELISA system. The experiment was performed twice. The original measurement numbers of the standard 14-3-3σ (concentration; 0.195~6.25nM) with step-by-step increasing concentrations and the CSF of 8 non-AD patients are shown in the Abs450 column. Next, the average of the two values ​​is calculated, see the Average Abs450 column. PBS was used as a negative control. The Del Abs 450nm value was obtained by subtracting the PBS value from each average value (mean). (b) A standard dose-response curve was prepared by measuring the step-by-step increasing concentrations of recombinant 14-3-3σ. It is inferred from this that the minimum limit of detection using this ELISA is 0.4nM. The CSF 14-3-3σ concentration of each data of Del Ab 450 nM in (a) was below the detection limit.

[0105] [ Fig.14 ] Figure S3 (Supplementary Figure 3 )<Trimeric adiponectin has a CLSP activation effect comparable to that of wild-type adiponectin> pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) was transfected into SH-SY5Y cells. Then, the cells were cultured in DMEM / F12-10% FBS containing / without 1nM trimer or wild-type (single) adiponectin and containing the indicated concentrations of GST-MycHis or CLSP-MycHis. 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing N2 supplement containing the same combination of proteins. Cells were collected 48 hours after the start of transfection and subjected to WST-8 assay and trypan blue exclusion cell death assay. Cell lysates were subjected to immunoblot analysis using APP antibody 22C11. "***" p<0.001; "ns" not significant.

[0106] [ Fig.15 ] Figure S4 (Supplementary Figure 4 )<Detailed analysis of the binding of CLSP to ApoE4 or adiponectin> (a, b) <Binding of apolipoprotein E4 to the C-terminal region of CLSP> A schematic diagram of the deletion mutants of CLSP is shown in (a). Apolipoprotein E4 (ApoE4) and adiponectin (ADN) with FLAG-tagged C-terminals were overexpressed in F11 neurohybrid cells by transfection. F11 cells were prepared as cell lysates 24 hours after transfection. In the immunoprecipitation of ApoE4-FLAG and ADN-FLAG using the FLAG antibody, 300 μg of cell lysate was used. Recombinant CLSP-MycHis (FL-MH) or CLSP deletion mutants with MycHis tags at the C-terminus were produced in bacteria and then purified. Next, SDS-PAGE and immunoblot analysis (Input) were performed on these immunoprecipitates and recombinant proteins using myc and FLAG antibodies. The ApoE4-FLAG and ADN-FLAG immunoprecipitates were mixed with recombinant CLSP-MycHis (FL-MH) or CLSP deletion mutants with MycHis tags at the C-terminus, incubated overnight at 4°C, and then washed thoroughly. Then, the Pull-down precipitate was subjected to SDS-PAGE using myc antibody and FLAG antibody, and immunoblot analysis was performed. (c) <Binding of CLSP to the collagen homologous region of adiponectin> The collagen homologous region of adiponectin (ADNCol) with 6×His and G (HisG) tags at the N-terminus was produced in bacteria. In addition, CLSP-FLAG was overexpressed in F11 neurohybrid cells by transfection. The purified recombinant FLAG-CLSP and control (vector) of immunoprecipitation were subjected to SDS-PAGE using HisG-ADNCol and FLAG antibody, and immunoblot analysis was performed using FLAG and HisG antibodies (Input; left panel). Next, the purified recombinant HisG-ANDCol and immunoprecipitated CLSP-FLAG or control (vector) were mixed, incubated overnight at 4°C, and then washed thoroughly. Then, the Pull-down precipitate was subjected to SDS-PAGE using FLAG antibody and HisG antibody, and immunoblot analysis was performed (Co-IP; right panel).

[0107] Fig.16 Figure S5 (Supplementary Figure 5 ) <No relationship between age and CSF adiponectin concentration> The raw data of adiponectin levels and age were plotted for all subjects in Table 1 and Table S1 (X-axis: age; Y-axis: CSF adiponectin concentration). The correlation coefficient was 0.0055.

[0108] Fig.17 Figure S6 (Supplementary Figure 6 ) <The level of SH3BP5 in neurons is not affected by advanced age>​​ Fig.11 The SH3BP5 data for AD patients or ALS patients shown in C were divided into two groups according to age and compared. One group consisted of people under 70 years old, and the other group consisted of people 71 years old and above. The mean ± SEM relative intensity of SH3BP5 in the two groups was 57439 ± 14465 arbitrary units and 65237 ± 7976 arbitrary units (unpaired T test, p = 0.6328, t = 0.49, R squared = 0.021, degrees of freedom = 11, p value of F test = 0.24).

[0109] Fig.18 Figure L1 <The minimum concentration of CLSP1-61 that completely inhibits V642I-APP-induced neuronal cell death is 500 pM> (a, b) SH-SY5Y cells were transfected with the pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP). Then, the cells were cultured in DMEM / F12-10% FBS containing the indicated concentrations of GST-MycHis or CLSP(1-61)-MycHis. Twenty-four hours after transfection, the medium was changed to DMEM / F12 containing N2 supplement with the same concentrations of GST-MycHis or CLSP(1-61)-MycHis. Cells were harvested 48 hours after transfection, and trypan blue exclusion cell viability, WST8, and calcein assays were performed. In addition, immunoblot analysis of cell lysates was performed using the APP antibody 22C11.

[0110] Fig.19 Figure L2 <CLSP inhibitor does not block the inhibitory effect of CLSP1-61 on V642I-APP-induced neuronal cell death> The pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) was transfected into SH-SY5Y cells. Then, the cells were cultured in DMEM / F12-10% FBS containing 10 nM of BSA, ApoE3, 14-3-3σ, or calreticulin and 1 nM of GST-MycHis or CLSP(1-61)-MycHis simultaneously. Twenty-four hours after transfection, the medium was changed to DMEM / F12 containing N2 supplement with the same concentrations of BSA, ApoE3, 14-3-3σ, or calreticulin and GST-MycHis or CLSP(1-61)-MycHis simultaneously. Cells were harvested 48 hours after transfection, and trypan blue exclusion cell viability, WST8, and calcein assays were performed. Immunoblot analysis of cell lysates was performed using the APP antibody 22C11.

[0111] ​​​ Fig. 20 ] Figure L3 <The collagen homology region of adiponectin enhances CLSP activity> The pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) was transfected into SH-SY5Y cells. The cells were then cultured in DMEM / F12-10% FBS containing 1nM BSA, adiponectin (FL) or the collagen homology region of adiponectin (Col) and 1nM or 50pM GST-MycHis or CLSP-MycHis. 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing N2 supplement containing the same combination of proteins. Cells were collected 48 hours after the start of transfection, and trypan blue exclusion of cell mortality, WST8 and calcein were determined. Cell lysates were immunoblotted using APP antibody 22C11.

[0112] [ Fig.21 ] Figure L4 <The minimum concentration of the collagen homology region of adiponectin to fully activate 50pM CLSP is 500pM> pcDNA3.1 / MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) was transfected into SH-SY5Y cells. Then, the cells were cultured in DMEM / F12-10% FBS containing 500μM BSA, 250μM adiponectin (FL) or the collagen homology region (Col) of adiponectin at the indicated concentrations, and 50pM GST-MycHis or CLSP-MycHis. 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing N2 supplement containing the same combination of proteins. Cells were collected 48 hours after the start of transfection, and trypan blue exclusion of cell mortality, WST8 and calcein were determined. Cell lysates were subjected to immunoblot analysis using the APP antibody 22C11.

[0113] [ Fig. 22 Figure L5 <CLSPCOL has potent AD protective activity> Transfect the pcDNA3.1 MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) into SH-SY5Y cells. Then, culture the cells in DMEM / F12-10% FBS containing 1 nM of GST-MycHis, CLSP1-61-MycHis, CLSP-MycHis, or the indicated concentration of CLSPCOL or wt-CLSPCOL. Twenty-four hours after transfection, exchange the medium to DMEM / F12 containing N2 supplement with the same concentration of reagents. Harvest the cells 48 hours after the start of transfection and perform trypan blue exclusion cell death assay. Immunoblot analysis of cell lysates was performed using the APP antibody 22C11.

[0114] Fig.23 Figure L6 <CLSPCOL effectively penetrates the blood-brain barrier> (a) As shown in Table L1, simulate the standard dose-response curve by measuring the absorbance at 450 nM for wt-CLSPCOL and CLSPCOL with increasing concentrations. (b) One hour after intraperitoneal injection of 10 nmol of GST-MycHisG, CLSPCOL, and wt-CLSPCOL, collect the brain and serum from mice for ELISA. As shown in Table L1, use ELISA to measure the concentrations of CLSPCOL and wt-CLSPCOL in brain lysates containing interstitial fluid (ISF) and serum. (c) Calculate the ratio of ISF to serum concentration and present it.

[0115] Fig.24 Figure X1 <CLSPCOL is not hindered by ApoE3 and 14-3-3σ, but is mildly hindered by calreticulin> Transfect the pcDNA3.1 MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) into SH-SY5Y cells. Then, culture the cells in DMEM / F12-10% FBS containing 100 pM of GST-MycHis or CLSPCOL and 1 nM of ApoE3, 14-3-3σ, or calreticulin. Twenty-four hours after transfection, exchange the medium to DMEM / F12 containing N2 supplement with the same concentration of reagents. Harvest the cells 48 hours after the start of transfection and perform trypan blue exclusion cell death assay. Immunoblot analysis of cell lysates was performed using the APP antibody 22C11.

[0116] Fig.25 ​​​Figure X2 <CLSPCOL began to be blocked by calreticulin at a concentration more than 10 times higher> Transfect the pcDNA3.1MycHis vector (vector) or pcDNA3.1 / MycHis-V642I-APP (V642I-APP) into SH-SY5Y cells. Then, culture the cells in DMEM / F12-10% FBS containing GST-MycHis (1 nM), CLSP1-61-MycHis (1 nM), CLSPCOL (100 pM) or wt-CLSPCOL (100 pM) and the indicated concentration of calreticulin or BSA. 24 hours after transfection, change the medium to DMEM / F12 supplemented with N2 containing the same concentration of reagents. Collect the cells 48 hours after transfection and perform trypan blue exclusion cell death assay. Immunoblot analysis was performed on cell lysates using the APP antibody 22C11. Detailed Description of the Invention

[0117] [CLSP Derivative]

[0118] Amino acid sequence (I) consisting of 22 amino acids (amino acids 40-61) contained in calmodulin-like skin protein (CLSP) (amino acid sequence 1):

[0119] TGKNLSEAQLRKLISEVDS(or G)DGD (amino acid single letter representation) (I) is called the endogenous human peptide homologous region ( E ndogenous H umanin-Homogenous R egion: EHR) or endogenous human peptide-like domain (( E ndogenous H umanin-Like D omain: EHD), which plays a central role in the inhibition of CLSP-mediated neuronal cell death (Patent Document 1).

[0120] The CLSP derivative of the present invention is characterized in that it contains the endogenous human peptide homologous region (EHR) as the active center for inhibiting the dysfunction or neuronal cell death of neurons related to Alzheimer's disease (CLSP activity or CLSP inhibitory activity), and does not contain the region to which the inhibitor or inhibitory substance (CLSP inhibitor) of this activity binds. As the region to which the inhibitor binds, for example, the amino acid sequence (amino acids 62-146) of the C-terminal region of CLSP (SEQ ID NO: 1) can be cited.

[0121] In the present invention, "the activity of inhibiting the dysfunction or cell death of nerve cells associated with Alzheimer's disease" refers to inhibiting or antagonizing at least one of the dysfunction or cell death in nerve cells, regardless of the cause or causal relationship. The inhibition of nerve cell death may be significant, even if it is not complete inhibition. The inhibitory activity of nerve cell death can be tested according to the methods described in the following examples or other methods described (for example, refer to International Publication No. WO00 / 14204). For example, CLSP activity can be measured using various nerve cell death assays as the inhibitory activity of V642I-APP-induced nerve cell death.

[0122] Furthermore, the binding of the inhibitor to the CLSP can be measured by any method / means (measurement system) known to those skilled in the art as described in the examples of this specification, for example, by immunoblotting analysis, pull-down analysis, Nano-Glo HiBiT extracellular detection system, ELISA, etc.

[0123] Here, as specific examples of EHR, there can be listed: amino acid sequence (I): TGKNLSEAQLRKLISEVDS (or G) DGD (single letter representation of amino acids) (I), or an amino acid sequence consisting of 22 amino acids as described in claim 1 of Patent Document 1. In addition, as an example of the region to which the inhibitor binds, there can be listed: the amino acid sequence (amino acids 62 to 146) of the C-terminal region of CLSP (SEQ ID NO: 1).

[0124] Therefore, suitable examples of the CLSP derivatives of the present invention include polypeptides consisting of the following amino acid sequences:

[0125] (1) Amino acid sequence of the N-terminal region of CLSP (amino acids 1 to 61);

[0126] (2) an amino acid sequence in the amino acid sequence of (1) above, in which one or more (e.g., about 2 to 5) amino acids are deleted, substituted or inserted in an amino acid sequence other than EHR contained in the amino acid sequence; or

[0127] (3) An amino acid sequence of the above (1) that is 90% or more, preferably 95% or more, and more preferably 98% or more identical to an amino acid sequence other than EHR contained in the amino acid sequence.

[0128] The CLSP derivatives of the present invention are characterized in that they have the same degree of CLSP activity as the wild-type CLSP and do not contain the region to which the inhibitor binds, and therefore are substantially (significantly) not inhibited or inhibited by the inhibitor on the CLSP activity. It should be noted that the CLSP derivatives of the present invention also include various mutants such as deletion mutants and fusion proteins (hybrid polypeptides) containing HER, but do not include polypeptides consisting only of HER.

[0129] On the other hand, the CLSP inhibitor is not particularly limited to its structural characteristics, and is, for example, a substance that shows a significant inhibitory (inhibitory) effect on CLSP activity at a concentration equal to or 5 times higher than the CLSP concentration in the culture medium, such as apolipoprotein E (ApoE), 14-3-3 protein, and calreticulin. In particular, it shows a high inhibitory effect on the CLSP activity of ApoE (ApoE3 and ApoE4).

[0130] [Adiponectin and its derivatives]

[0131] Furthermore, the present invention has revealed that adiponectin (SEQ ID NO: 3) binds to EHR in the CLSP1-61 region of CLSP and the CLSP derivatives of the present invention through a polypeptide (SEQ ID NO: 2) which is its collagen homology region (ADNCol), thereby enhancing their CLSP activity; and that adiponectin and the polypeptide also have the following effects: protecting the CLSP from the inhibitory or suppressive effects of the above-mentioned inhibitors on CLSP activity, or rendering the inhibitors ineffective.

[0132] Therefore, a polypeptide consisting of the following amino acid sequence (hereinafter also referred to as "adiponectin and its derivatives") can be used as an enhancer or protector of the CLSP activity possessed by CLSP or the CLSP derivatives of the present invention:

[0133] (1) the amino acid sequence shown in SEQ ID NO: 2 (ADNCol);

[0134] (2) an amino acid sequence comprising the amino acid sequence (ADNCol) of (1) above, for example, adiponectin as shown in SEQ ID NO: 3;

[0135] (3) an amino acid sequence in which one or more (e.g., about 2 to 5) amino acids are deleted, substituted or inserted in an amino acid sequence other than ADNCol contained in the amino acid sequence of adiponectin as shown in SEQ ID NO: 3; or

[0136] (4) An amino acid sequence having 90% or more, preferably 95% or more, and more preferably 98% or more identity with an amino acid sequence other than ADNCol contained in the amino acid sequence of adiponectin shown in SEQ ID NO: 3. It should be noted that these polypeptides can form multimers such as trimer adiponectin.

[0137] It should be noted that "CLSP" includes not only the polypeptide shown in SEQ ID NO: 1 described in this specification, but also various CLSP-related (similar) polypeptides having CLSP activity as described in Patent Document 1. In addition, regarding such CLSP activity, "inhibition" and "hindrance" of neuronal dysfunction or neuronal cell death associated with Alzheimer's disease are synonymous. Moreover, regarding the activity of the enhancing or protecting agent of the present invention, "protection", "maintenance" and "maintaining" are synonymous.

[0138] [Fusion protein of CLSP derivatives, etc. and adiponectin derivatives, etc.]

[0139] Furthermore, the present invention also relates to a fusion protein (hybrid polypeptide) comprising CLSP or a CLSP derivative as an example of the above-mentioned CLSP derivative and adiponectin or an adiponectin derivative. The fusion protein has a potent CLSP activity and is not inhibited by a CLSP inhibitor, or even if it is inhibited, it is only slightly.

[0140] In particular, as a suitable example, a fusion protein (CLSPCOL) consisting of the amino acid sequence (amino acids 1 to 61) of the N-terminal region of CLSP and ADNCol can efficiently penetrate the blood-brain barrier and be transferred to the CNS.

[0141] The fusion protein involved may contain any amino acid sequence other than the polypeptide constituting each region (element) as long as it does not impair its specified activity. For example, in order to improve the stability of the three-dimensional structure of the protein, a linker sequence consisting of an appropriate amino acid sequence may be inserted between the regions. Alternatively, for example, for the purpose of improving in vivo stability (half-life in plasma, etc.), any amino acid sequence known to those skilled in the art, such as an immunoglobulin constant region found in a known fusion protein, may be added to the C-terminal side.

[0142] Such additional / insertion sequences can be appropriately designed / modulated by those skilled in the art based on common technical knowledge, taking antigenicity, etc. It should be noted that regarding antigenicity, since CLSP1-61 and collagen homology regions are derived from endogenous human peptides, their antigenicity is presumed to be limited.

[0143] Furthermore, the connection order (N-terminal side or C-terminal side) of each region contained in the fusion protein is not particularly limited, and can be appropriately selected / adjusted by those skilled in the art.

[0144] Hereinafter, the CLSP derivatives, adiponectin and its derivatives, the CLSP composed of a polypeptide or the enhancer or protector of the CLSP activity possessed by the CLSP derivatives, and the polypeptide constituting the fusion protein of the present invention are also simply referred to as "the polypeptide of the present invention".

[0145] Regarding the polypeptide of the present invention, in order to determine the identity of the sequences in two amino acid sequences, the sequences are pre-treated to reach a more optimal state. For example, by inserting a gap in one sequence, the comparison with another sequence is optimized. Afterwards, the amino acid residues or bases at each site are compared. In the case where a certain site in the first sequence has the same amino acid residue or base as the corresponding site of the second sequence, these sequences are identical at their sites. The identity in the two sequences is expressed as the percentage of the number of identical sites between the sequences to the total number of sites (total amino acids or total bases).

[0146] According to the above principle, the identity between two amino acid sequences can be determined by any method known to those skilled in the art. For example, it can be determined according to the algorithm of Karlin and Altshul (Proc. Natl. Acad. Sci. USA 87: 2264-2268, 1990 and Proc. Natl. Acad. Sci. USA 90: 5873-5877, 1993). The BLAST program using this algorithm was developed by Altshul et al. (J. Mol. Biol. 215: 403-410, 1990).

[0147] Moreover, Gapped BLAST is a program that determines identity with higher sensitivity than BLAST (Nucleic Acids Res. 25:3389-3402, 1997). The above program is mainly used to retrieve sequences that show a high degree of identity with respect to a provided sequence from a database. These can be used, for example, at the website of the National Center for Biotechnology Information on the Internet.

[0148] Alternatively, as the identity between sequences, the value determined using the BLAST 2 Sequences software developed by Tatiana A. Tatusova et al. (FEMS Microbiol Lett., 174: 247-250, 1999) can also be used. This software is available on the website of the National Center for Biotechnology Information on the Internet and can also be obtained. The program and parameters used are as follows. In the case of amino acid sequences, as parameters for using the blastp program, Open gap: 11 and extension gap: 1 penalties, gap x_dropoff: 50, expect: 10, word size: 3, Filter: ON are used. In addition, the highly sensitive FASTA software (WRPearson and DJLipman, Proc. Natl. Acad. Sci. USA, 85: 2444-2448, 1988) can also be used to retrieve sequences showing identity from the database. All parameters are also used as default values ​​on the website.

[0149] The above-mentioned polypeptide of the present invention may also have a form that is changed by modification, addition, mutation, substitution or deletion using known methods. Such functional group changes can be made using any method known to those skilled in the art, for example, to protect the polypeptide, control the stability or tissue metastasis of the polypeptide, or control the activity of the polypeptide.

[0150] That is, the polypeptide of the present invention can be naturally modified by post-translational modification, etc. In addition, it can also be artificially modified. Modifications include: modifications of the main chain of the peptide, the amino acid side chain, the amino terminus, or the carboxyl terminus. In addition, the polypeptide can be branched or cyclic. Modifications include: acetylation, acylation, ADP ribosylation, amidation, covalent bonds of [flavin, nucleotides, nucleotide derivatives, lipids, lipid derivatives, or phosphatidylinositol], cross-linking formation, cyclization, disulfide bond formation, demethylation, pyroglutamation, carboxylation, glycosylation, hydroxylation, iodination, methylation, myristoylation, oxidation, phosphorylation, ubiquitination, etc., but are not limited to these. Moreover, the above-mentioned peptides or polypeptides can also form any salts and esters known to those skilled in the art.

[0151] Furthermore, the polypeptide of the present invention may also form a fusion polypeptide with any known neurotropic peptide, and such a fusion polypeptide can be easily synthesized according to any method known to those skilled in the art.

[0152] The polypeptide of the present invention can be prepared from cell lines of appropriate species such as humans and mice based on gene or amino acid sequence information about CLSP and adiponectin known to those skilled in the art, and can be produced using known peptide synthesis techniques. In addition, it is also possible to produce by introducing vectors containing DNA encoding them into appropriate host cells, etc., using genetic engineering methods known to those skilled in the art to express them. In this case, for example, in the case of CLSP derivatives or adiponectin derivatives, they can be prepared by appropriately changing a part of their amino acid sequence by methods / means known to those skilled in the art.

[0153] Such a vector is in any form known to those skilled in the art, such as a plasmid or a viral vector, and can be easily prepared by any method known to those skilled in the art. The vector obtained in this way contains, in addition to the coding region of the site-specific recombinase of the present invention, non-coding sequences (including nuclear transfer signals, tag sequences, non-transcribed sequences, non-translated sequences, promoters, enhancers, repressors, transcription factor binding sequences, splicing sequences, poly A addition sequences, IRES, mRNA stabilization / destabilization sequences, etc.) at 5' and 3', and functions as an expression vector.

[0154] Suitable host cells can be easily transformed by any method known to those skilled in the art using such a vector, for example, lipofection, calcium phosphate method, and various physical methods such as electroporation and particle gun.

[0155] The host cell is not particularly limited, and for example, mammalian cells including human, monkey and mouse, plant cells, insect cells, and bacteria such as Escherichia coli can be used. The transformed cells prepared in this way can be cultured under any conditions known to those skilled in the art, and the polypeptide of the present invention, etc., which is the target, can be easily prepared from appropriate components such as the cultured cells or their culture supernatant.

[0156] The polypeptide of the present invention can be used as an active ingredient of a pharmaceutical composition for inhibiting neuronal dysfunction or neuronal cell death associated with Alzheimer's disease, for example, a pharmaceutical composition for preventing or treating diseases accompanied by memory impairment or neurodegeneration associated with Alzheimer's disease.

[0157] Moreover, using the polypeptide of the present invention, in addition to Alzheimer's disease, diseases accompanied by memory impairment or neurodegeneration, such as diseases caused by cell death of nerve cells due to cerebral ischemia (T.Kirino, 1982, Brain Res., 239: 57-69) can be prevented / treated. In addition, Parkinson's disease accompanied by dementia (MH Polymeropoulos et al., 1997, Science, 276: 2045-2047), diffuse Lewy body disease (MG Spillantini et al., 1998, Proc. Natl. Acad. Sci. USA, 95: 6469-6473), dementia associated with Down syndrome, etc. are also the objects of treatment or prevention. In addition, since APLP1, a molecule similar to APP, is considered to be a pathogenic gene of congenital nephrotic syndrome (Lenkkeri, U et al., 1998, Hum. Genet. 102: 192-196), renal diseases such as nephrotic syndrome are also targets for treatment or prevention.

[0158] The pharmaceutical composition of the present invention can be directly administered to the patient except the active ingredient itself, and also can utilize known pharmaceutics method to make preparation.For example, consider making preparation after administration with pharmacologically acceptable carrier or medium, specifically with sterile water or physiological saline, vegetable oil, emulsifier, suspending agent, surfactant, stabilizer, sustained release agent etc. suitable combination.The pharmaceutical composition of the present invention can be the form such as aqueous solution, tablet, capsule, lozenge, buccal tablet, elixir, suspension, syrup, nasal drops or inhalation liquid.The content of peptide or polypeptide as active ingredient can be suitably determined according to purpose of use and preparation form etc.

[0159] Administration to the patient can be carried out according to the properties of the active ingredient, for example, by transdermal, intranasal, transbronchial, intramuscular, intraperitoneal, intravenous, intraspinal, intraventricular or oral administration, but is not limited to these. In the case of treatment of neurodegenerative diseases, it is desired that the pharmaceutical composition of the present invention is introduced into the central nervous system by any appropriate route including intravenous, intraspinal, intraventricular or intradural injection. The dosage and method of administration vary according to the tissue metastasis of the active ingredient of the pharmaceutical composition of the present invention, the purpose of treatment, the weight or age of the patient, the symptoms, etc., but can be appropriately selected by those skilled in the art. For example, once to multiple times a day, tens of μl of the drug can be administered within an appropriate period for each treatment. The active ingredient can be set to a concentration in the range of about 10 pmol to 100 nmol, for example.

[0160] Thus, the pharmaceutical composition of the present invention can be widely used for preventing or treating diseases accompanied by neuronal cell dysfunction or neuronal cell death, such as Alzheimer's disease, or diseases accompanied by memory impairment or neurodegeneration.

[0161] Therefore, the present invention relates to: a method for inhibiting dysfunction or cell death of nerve cells, comprising a step of contacting the polypeptide of the present invention with nerve cells; a method for treating diseases such as Alzheimer's disease accompanied by cell dysfunction or death of nerve cells, or a disorder accompanied by memory impairment or neurodegeneration, comprising a stage of administering the pharmaceutical composition of the present invention to an animal subject (individual) such as a human suffering from or suspected of suffering from the disease or disorder; and a method for treating a disease accompanied by a neurodegenerative disorder.

[0162] The present invention also relates to a method for detecting the inhibitory activity of the polypeptide of the present invention on the dysfunction or cell death of nerve cells, the method comprising: step (a), inducing the dysfunction or cell death of nerve cells in the presence / absence of a CLSP inhibitor and in the presence / absence of the polypeptide; step (b), detecting the cell dysfunction or cell death of nerve cells; and step (c), comparing the dysfunction or cell death of nerve cells in the presence / absence of the polypeptide, etc.

[0163] According to the above method, the activity of the polypeptide of the present invention to inhibit neuronal dysfunction or cell death, and the activity of enhancing or protecting the CLSP activity of CLSP or CLSP derivatives from inhibition by CLSP inhibitors can be detected.

[0164] Specific operations can be performed, for example, according to the method described in this specification. This method can be used to determine whether the polypeptide of the present invention has an inhibitory effect on cell death in various cells, or to quantify its inhibitory effect. There is no particular limitation on the cells, and various cells that can cause cell death are used. In addition, the induction of cell death can use a known cell death induction system according to the respective cells. In addition, using nerve cells, it can also be used to detect the effects of various conditions such as various stimuli, environmental changes, or gene expression of the polypeptide of the present invention, etc. on inducing nerve cell death. In addition, such detection can be used to detect the differences in sensitivity to the polypeptide of the present invention, etc. in nerve cell death that may exist between biological species or subspecies or individuals. Thus, for example, the effectiveness of the polypeptide of the present invention can be studied between nations, races or individuals. Utilizing such a method, for example, detailed conditional studies for clinical applications can be carried out.

[0165] In addition, the present invention also relates to a method for screening a substance (test substance) that modulates the inhibitory activity of the polypeptide or CLSP of the present invention on the functional disorder of nerve cells or the death of nerve cells. The method can be used to determine the effect (influence) of the test substance on the inhibitory activity of the polypeptide or CLSP of the present invention on the functional disorder of nerve cells or the death of nerve cells. It is believed that the polypeptide or CLSP of the present invention acts on the surface of nerve cells to exert a cell death inhibitory effect. If this method is used, it is possible to verify the effect of candidate compounds that can hinder the contact of these polypeptides with the cell surface or vice versa, the candidate compounds that can promote the contact.

[0166] The screening method includes the following steps: step (a), inducing dysfunction or death of nerve cells in the presence of the polypeptide or CLSP of the present invention and in the presence or absence of a test substance; step (b), detecting dysfunction or death of nerve cells; and step (c), selecting a substance that regulates the inhibitory activity of the polypeptide or CLSP of the present invention on dysfunction or death of nerve cells. In step (c), the situation in any control can be compared. For example, in step (c), a compound that promotes or inhibits dysfunction or death of nerve cells in the presence of a test substance compared to the situation in which the test substance is detected in the absence of the test substance can be selected. Compounds that promote dysfunction or death of nerve cells become candidates for compounds that hinder the action of the polypeptide or CLSP of the present invention, and compounds that further inhibit death of nerve cells become candidates for compounds that further promote the action of the polypeptide or CLSP of the present invention.

[0167] In addition, in the above-mentioned screening, the situation of other compounds other than the test substance can also be used as a control. For example, in step (b), other compounds that can regulate the functional disorder of nerve cells or the inhibition of nerve cell death by the polypeptide or CLSP of the present invention can also be used for detection, and in step (c), a compound that promotes or inhibits the functional disorder of nerve cells or the death of nerve cells in the presence of the test substance used in step (a) can also be selected compared with the situation in the presence of the compound. In such a screening, a compound having a higher effect than existing compounds in terms of the ability to regulate the functional disorder of nerve cells or the inhibition of nerve cell death by the polypeptide or CLSP of the present invention can be screened.

[0168] As the test substance used for the above screening, for example, there can be listed: purified protein (including antibody), expression products of gene library, library of synthetic peptide, cell extract, cell culture supernatant, library of synthetic low molecular compound, natural materials such as soil, solution containing bacterial release substances such as actinomycete broth, etc., but it is not limited to these. Induction of neuronal cell death or administration of the polypeptide of the present invention can be carried out according to any method known to those skilled in the art.

[0169] There is no particular limitation on the period of applying the test substance to the cells, and the test substance may be applied before, after, or simultaneously with the application of the polypeptide of the present invention. There is no limitation on the method of applying the test sample, and if it is a cultured cell system, it may be added to the culture medium, for example. In addition, if it is a nucleic acid, it may be introduced into the cell. The test sample may be applied by any other administration method.

[0170] Substances evaluated by examining the effects of the above compounds or substances obtained by screening become candidates for compounds that regulate the activity of the polypeptide of the present invention, and are considered to be useful in preventing or treating diseases including Alzheimer's disease.

[0171] The present invention also relates to a method for screening a substance (compound) that binds to the polypeptide of the present invention, the method comprising: step (a), contacting a test substance with the polypeptide; step (b), detecting the binding activity of the polypeptide with the test substance; and step (c), selecting a substance having the activity of binding to the polypeptide.

[0172] The polypeptide of the present invention can be used for screening as a soluble polypeptide and in a form bound to a carrier according to the screening method. The polypeptide of the present invention can be labeled. Examples of the label include radioisotope labeling, fluorescent substance labeling, biotin or digoxigenin labeling, and addition of a tag sequence.

[0173] As the test substance for screening, for example, there can be listed: purified protein (including antibodies), expression products of gene libraries, libraries of synthetic peptides, cell extracts, cell culture supernatants, libraries of synthetic low molecular weight compounds, natural materials such as soil, solutions containing bacteria-released substances such as actinomycete broth, etc., but are not limited to these. The test substance is used after being appropriately labeled as needed. As labels, for example, there can be listed: radiolabels, fluorescent labels, etc., but are not limited to these.

[0174] For example, in the case of screening for proteins that bind to the polypeptide of the present invention, a cell extract of a tissue or cell predicted to be expressing a protein that binds to the polypeptide of the present invention is loaded onto an affinity column to which the polypeptide of the present invention is fixed, and the protein that specifically binds to the column is purified, thereby screening for proteins that bind to the polypeptide of the present invention.

[0175] A cDNA library using a phage vector is then prepared from tissues or cells (e.g., cerebral cortical tissue, or neural cells such as F11) predicted to be expressing a protein that binds to the polypeptide of the present invention, and plaques are formed on agarose. Screening is performed by protein blotting using labeled polypeptides of the present invention, or the method may be implemented according to the following "two-hybrid system": DNA binding peptides such as the GAL4 DNA binding region and transcription activation peptides such as the GAL4 transcription activation region are expressed as fusion proteins of the polypeptide of the present invention and the test protein, respectively, and the binding of the polypeptide of the present invention and the test protein is detected by expressing a reporter gene connected downstream of the promoter having the binding sequence of the DNA binding peptide.

[0176] It is also conceivable to screen for receptors of the polypeptide of the present invention by the screening of the present invention. In this case, the test sample is preferably prepared from tissues or cells predicted to express the receptor, such as cerebral cortical tissue, neural cell lines, or neuroblastoma or teratoma cells. Examples of neural cell lines include F11 cells, PC12 cells (LA Greene and AS Tischler, 1976, Proc. Natl. Acad. Sci. USA, 73: 2424-2428), NTERA2 cells (J. Skowronski and MF Songer, 1985, Proc. Natl. Acad. Sci. USA, 82: 6050-6054), SH-SY5Y cells (L. Odelstad et al., 1981, Brain Res., 224: 69-82), and the like.

[0177] In addition, it is also considered to make synthetic compounds, natural object libraries or random phage peptide display libraries etc. and immobilized polypeptide effects of the present invention, screen the molecules of combination. In addition, it is also possible to screen (for example, BIAcore company manufactures etc.) by utilizing the detection of the combination of surface plasma resonance phenomenon. These screenings can also be carried out by utilizing the high throughput screening of combinatorial chemistry technology.

[0178] The compounds that bind to the polypeptide of the present invention obtained through the screening of the present invention become candidates for compounds that regulate the activity of the polypeptide of the present invention, and are considered to be used in the prevention or treatment of diseases including Alzheimer's disease.

[0179] The present invention will be further described in detail below based on the examples. It should be noted that the technical scope of the present invention is not limited by these descriptions.

[0180] Example

[0181] [Identification of multiple CLSP interactors]

[0182] In previous studies, multiple proteins such as 14-3-3σ, 14-3-3β, calreticulin, ERp27, nucleolar proteins, annexin II, and annexin V were identified as putative CLSP binding factors (15). Among these, proteins reported to be secreted into the extracellular space were selected for analysis in the present invention. In addition, the present invention newly discovered that apolipoprotein E (ApoE) and adiponectin bind to CLSP ( Figure 1 ).

[0183] [Apolipoprotein E, 14-3-3 protein and calreticulin are inhibitors of CLSP]

[0184] As shown above (5), overexpression of V642I-amyloid β precursor protein (V642I-APP) caused cell death in SH-SY5Y neuroblastoma cells, but V642I-APP-induced neuronal death was completely inhibited by co-culture with recombinant CLSP produced in bacteria (500 pM or 1 nM). Figure 2 a) Based on the dose-response analysis, it is estimated that the 50% effective concentration of CLSP produced in bacteria is about 200 pM ( Figure 2 a), showing a slightly greater than 50% effective concentration of recombinant CLSP produced in mammalian cells (5). Interestingly, the addition of recombinant apolipoprotein E3 or E4 (ApoE3 or ApoE4) to the culture medium dose-responsively blocked CLSP-mediated protection against V642I-APP-induced neuronal death ( Figure 2 b and c). ApoE3 at a concentration of 5 nM completely blocked the effect of 1 nM CLSP ( Figure 2 b), on the other hand, ApoE4 at a concentration of 1 nM completely blocked the effect of 1 nM CLSP ( Figure 2 c). The results show that the inhibitory effect of ApoE4 is slightly stronger than that of ApoE3. Similarly, by co-culturing with recombinant 14-3-3σ, the protection against V642I-APP-induced neuronal death mediated by CLSP was inhibited ( Figure 3 a). The blocking effect of 14-3-3σ on 10 nM CLSP was initially observed at 10 nM concentration, and complete blocking was achieved in this particular experiment when 20 nM of recombinant 14-3-3σ was added. Other 14-3-3 proteins also blocked CLSP-mediated blocking of V642I-APP-induced neuronal cell death, with complete blocking achieved at 50 nM of recombinant 14-3-3σ ( Figure 3 b~e). Similarly, calreticulin at a concentration of 50 nM completely blocked the effect of 10 nM CLSP ( Figure 3 f). Therefore, these results confirm that the CLSP inhibitors show complete CLSP inhibitory effects at concentrations equal to or 5 times higher than the CLSP concentration in the culture medium. In contrast, annexin II, annexin IV, or adiponectin did not show inhibitory activity even at concentrations 5 or 10 times higher than the CLSP concentration in the culture medium ( Figure 3 f and Figure S-1).

[0185] [Adiponectin maintains CLSP activity even in the presence of very high concentrations of CLSP-inhibiting substances]

[0186] The concentration of CLSP in human cerebrospinal fluid (CSF) is estimated to be 3 to 6 nM (14). ApoE is known to be produced by astrocytes and microglia, and a considerable proportion of ApoE is mobilized together with lipids and other apolipoproteins to form high-density lipoprotein-like lipoproteins in the human CNS (16, 17). The concentration of ApoE in human CSF is estimated to be 40 to 200 nM (18-20). On the other hand, the concentration of 14-3-3σ in human CSF is estimated to be much lower than 1 nM (see Figure S2). In addition, based on previous studies, the concentration of 14-3-3γ in human CSF is estimated to be lower than 1 nM (21). In addition, the concentration of calreticulin in human serum is estimated to be around 10 pM (22), but the concentration in human CSF has not been measured so far. Combining these findings, the concentration of ApoE as a whole exceeds the concentration required to completely inhibit the function of CLSP by more than 10 times. On the other hand, the concentration of other inhibitory substances is likely to be insufficient to inhibit CLSP in the human CNS.

[0187] As described above, since a very large amount of CLSP-inhibiting substances (mainly composed of ApoE) exist in the human CNS, CLSP activity appears to be zero in vivo. However, based on previous studies (35), it is natural to assume that CLSP activity exists at least in normal humans. Therefore, the hypothesis of which of the other CLSP-binding substances protects CLSP from the influence of CLSP-inhibiting substances to maintain activity was studied next. Therefore, recombinant proteins of candidate annexin II, annexin V or adiponectin were added at a concentration equal to the concentration of ApoE3 to a cell death assay system containing 1nM CLSP and 10nM ApoE3. As a result, adiponectin completely inactivated the ApoE3-mediated inhibition of CLSP activity (CLSP protective activity) ( Figure 4 a). On the other hand, neither Annexin II nor Annexin V showed such neutralizing activity at the concentrations tested ( Figure 4 b and c). In order to determine the minimum ineffective concentration of adiponectin, the concentration of adiponectin was then gradually reduced. As a result, adiponectin completely inhibited the CLSP inhibitory activity of ApoE4 at the following concentration ratio (CLSP, 1 nM; ApoE4, 10 nM: adiponectin, 1 nM) ( Figure 5 a). Moreover, even when the concentration was further reduced to 100 pM, adiponectin partially inhibited the CLSP inhibitory activity of ApoE4 (CLSP, 1 nM: ApoE4, 10 nM: adiponectin, 100 pM). On the other hand, even when the concentration of ApoE4 was increased to 50 nM, the protective effect of 1 nM adiponectin was not weakened at all ( Figure 5 b). These results show that even in the presence of an absolutely high concentration of ApoE4, 1 nM adiponectin maintains the concentration of active CLSP at a 100% effective level. Wild-type adiponectin spontaneously polymerizes in vivo to form three types of polymers. Moreover, the trimer is called low molecular weight adiponectin, the hexamer is called medium molecular weight adiponectin, and the octamer or more is called high molecular weight adiponectin (23). According to previous studies, it is known that medium molecular weight or high molecular weight adiponectin plays a core role in the metabolic regulatory activity mediated by the common adiponectin receptor (23). In this study, recombinant trimer adiponectin that does not form medium molecular weight or high molecular weight adiponectin was used, and it was found that the trimer adiponectin has the same CLSP enhancing effect as wild-type adiponectin (Figure S3). This result means that the medium molecular weight or high molecular weight multimerization of adiponectin is not necessary for the CLSP protective effect of adiponectin. According to previous studies, medium-molecular-weight or high-molecular-weight polymerized adiponectin shows higher activity in the metabolic regulation function mediated by the normal adiponectin receptor (23). In conclusion, the CLSP protective activity of adiponectin found here strongly supports the possibility that it is not an effect mediated by the normal adiponectin receptor. Further similar studies were conducted on CLSP inhibitory substances other than ApoE, and it was found that adiponectin also showed complete protective activity against the CLSP inhibitory effect of 14-3-3σ or calreticulin (CLSP, 1nM: 14-3-3σ or calreticulin, 2nM or 10nM: adiponectin, 1nM) ( Figure 6 ).

[0188] [Adiponectin enhances CLSP activity]

[0189] Furthermore, it has been found that, in addition to the above-mentioned CLSP protective effect, adiponectin also has the effect of enhancing CLSP activity itself. Figure 2 As shown in a, CLSP showed no inhibitory activity against V642I-APP-induced cell death at a concentration of 50 pM. However, in the presence of 200 pM adiponectin, CLSP showed almost complete or partial cell death inhibitory activity at a concentration of 50 pM or 25 pM, respectively ( Figure 7 a). This result shows that adiponectin enhances CLSP activity by binding to CLSP. The present inventors further found that even when the concentration of adiponectin administered simultaneously was reduced to 100 pM, adiponectin still showed some enhancement activity on CLSP at a concentration of 50 pM ( Figure 7 b) These results taken together show that the minimum adiponectin concentration for conferring complete cell death inhibitory activity to 50 pM CLSP, which is inactive alone, is 200-250 pM.

[0190] [The dissociation constant of the binding between adiponectin and CLSP is similar to the dissociation constant of the binding between apolipoprotein E4 and CLSP] As shown above, adiponectin completely ineffectively inhibited the CLSP activity of ApoE at a concentration 50 times higher (protective effect) ( Figure 4 and Figure 5 ). This potent CLSP protective effect conferred by adiponectin can be explained by two mechanisms as shown below. The first case: adiponectin and ApoE competitively bind to the same site of CLSP, and the binding affinity between adiponectin and CLSP is much stronger than the binding affinity between apolipoprotein E and CLSP (competitive antagonist). The second case: adiponectin binds to a CLSP region different from the ApoE binding region, thereby increasing CLSP activity by binding alone, and in the presence of CLSP inhibitory substances, inhibiting their inhibitory effects to maintain CLSP activity (non-competitive antagonist).

[0191] First, in order to find out how the presence of ApoE3 or ApoE4 affects CLSP and adiponectin or annexin II, or vice versa, the proteins were mixed with Sepharose 4B beads covalently bonded with CLSP (CLSP beads) and a pull-down assay (coprecipitation experiment) was performed to study the binding with CLSP ( Figure 8 a). As a condition, the concentration of CLSP, adiponectin, annexin II, ApoE3 or ApoE4 in the mixture was set to 1 nM. First, in the absence of other proteins, a certain amount of adiponectin, annexin II, ApoE3 or ApoE4 co-precipitated with the CLSP beads (lanes 2 to 4 and 7). Next, if co-precipitated with adiponectin, it was slightly reduced, but a considerable amount of ApoE3 or ApoE4 was still co-precipitated with the CLSP beads (lanes 5 and 8). Similarly, if co-precipitated with ApoE3 or ApoE4, it was slightly reduced, but a considerable amount of adiponectin was still co-precipitated (lanes 5 and 8). Importantly, the amount of co-precipitated ApoE is equal to or slightly more than the amount of co-precipitated adiponectin ( Fig.10 a). On the other hand, even with the addition of annexin II, the amount of ApoE3 or ApoE4 co-precipitated with CLSP was not reduced (lanes 6 and 9). On the contrary, in the presence of ApoE3 or ApoE4, annexin II was hardly co-precipitated with CLSP beads (lanes 6 and 9). These results show that the binding of adiponectin to CLSP is not inhibited by competing with ApoE to inhibit the inhibitory effect of ApoE (negation of the first possibility).

[0192] Next, the dissociation constants (Kd) for the binding between CLSP and adiponectin and between CLSP and ApoE4 were determined ( Figure 8 b and c). For this purpose, adiponectin or ApoE4 protein was conjugated to a 96-well plate. Recombinant CLSPs of various concentrations, labeled with HiBiT at the C-terminus as a tag for chemiluminescence, were added to the plate for simultaneous incubation. After washing, the amount of CLSP-HiBiT bound to adiponectin or ApoE4 on the wells was determined. The dissociation constants between adiponectin and CLSP, or between ApoE4 and CLSP, were determined by Scatchard analysis to be 8.8 or 7.8 pM, respectively ( Figure 8 c) The similar result of the two completely denies the first possibility mentioned above.

[0193] [Adiponectin and apolipoprotein E4 bind to different subdomains of CLSP]

[0194] To explore the second possibility, ApoE4-MycHis and adiponectin-MycHis were prepared and compared with previously constructed recombinant wild-type CLSP or CLSP deletion mutants (5, Fig. 9 a) Mix and perform pull-down assay ( Fig. 9 ). As a result, the mutant composed of only HER did not coprecipitate (bind) with ApoE4, while the other four CLSP mutants bound to ApoE4. On the other hand, only ΔN2 bound to adiponectin, while the other four mutants did not bind to it ( Fig. 9 b and c). These results mean that the ApoE4 binding site in CLSP is located outside the EHR, and the adiponectin binding site includes the EHR. Therefore, it was determined that adiponectin enhances and protects CLSP activity by binding to the EHR; and once adiponectin binds to the EHR, the inhibitory effect of the CLSP inhibitory substance caused by the non-EHR region is eliminated.

[0195] Further pull-down experiments revealed that adiponectin bound to the N-terminal region of CLSP consisting of amino acids 1-61, whereas ApoE4 did not bind to it (Fig. S4a and b). Fig. 9 Combined with the results of , this result means that ApoE binds to the C-terminal region (amino acids 62 to 146) of CLSP. In addition, through other similar experiments, the inventors also found that CLSP binds to the so-called "collagen homology region (ADNCol)" of adiponectin located in the central part of adiponectin (Figure S4c).

[0196] [Adiponectin concentration in CSF is significantly reduced in AD patients]

[0197] To estimate the concentration of adiponectin in the human CNS, the levels of adiponectin in CSF obtained from autopsy AD patients and non-AD cases were measured using an adiponectin ELISA assay kit (Table 1, Table S1 and Fig.10 As a result, it was found that the level of CSF adiponectin in AD patients was lower than that in non-AD cases ( Fig.10 b, Table 1). The mean ± SEM concentration of CSF adiponectin in AD patients was 0.31 ± 0.13 nM, while that in non-AD cases was 0.96 ± 0.19 nM (unpaired T test, p = 0.0065). This result suggests that, consistent with the results of previous studies (30), the level of adiponectin in the CSF of AD patients was significantly reduced. The adiponectin concentration of several non-AD cases was significantly lower than the average of non-AD cases and was almost equal to the average level of AD patients.

[0198] However, the mean age of AD patients (78.5±0.9 years) was significantly younger than the mean age of non-AD cases (86.3±1.4 years and older) (unpaired T test; p<0.0001 when "greater than" was considered as "equal to") (see Table S1). Therefore, age is more likely to affect the concentration of CSF adiponectin than the presence of AD. To investigate this possibility, cases aged 81 to 88 years were selected from all the cases in Table 1 (n=6 for AD, mean age±SEM=83.0±0.6 years; n=5 for non-AD, mean age±SEM=85.2±1.2 years; unpaired T test for age; p=0.11) (Table 2), and their CSF adiponectin levels were compared. As a result, it was found that the adiponectin level in the CSF of AD patients was significantly downregulated even in this age group (AD, 0.30±0.07 nM; non-AD, 1.41±0.16 nM; unpaired T test, p<0.0001) ( Fig.10 c, Table 2). Data from all subjects were further used to investigate whether CSF adiponectin levels were associated with age. As expected, there was no significant correlation between age and CSF adiponectin concentration (correlation coefficient = 0.0055) (Figure S5).

[0199] [SH3BP5, a core effector of the human peptide / CLSP-induced intracellular signaling pathway, is decreased in neurons of AD patients]

[0200] according to Fig.12 The results showed that the amount of CLSP / adiponectin complex equivalent to the amount of active CLSP in the brain of AD patients was less than that of non-AD cases. In order to obtain confirmation of this experimental fact (inside story), an attempt was made to quantify the intensity of CLSP-induced signaling in neurons by measuring the level of SH3BP5 in neurons. As a method for this purpose, the basis for measuring SH3BP5 is that previous studies have confirmed that SH3BP5 is a core effector of human peptide / CLSP-induced intracellular signaling mediated by htHNR, and if human peptide / CLSP binds to htHNR, the expression level increases (24). In fact, in this study (24), if CLSP / human peptide binds to htHNR, the transcription of SH3BP5 is activated via STAT3. The results showed that the expression level of SH3BP5 increased, and high levels of SH3BP5 directly formed a complex with JNK to block JNK, thereby blocking V642I-APP-induced death signals. For this purpose, first, the temporal lobe or occipital lobe (non-motor neuron area) of the brain obtained from autopsy AD patients and amyotrophic lateral sclerosis (ALS) patients was immunohistochemically stained using SH3BP5 antibody (Table 3 and Table S2). The reason for using the brain of an ALS patient as a negative control is that in ALS, neurodegeneration occurs only in the motor neurons of the motor area of ​​the temporal lobe, and no abnormality is found in the neurons of the temporal lobe or occipital lobe. As a result of this experiment, it was found that the level of SH3BP5 was reduced in the neurons of the cortex of AD compared with ALS (unpaired T test, p = 0.0256) ( Fig.11 a, b and c, Table 3). Considering that the average age of AD patients is higher than that of ALS patients (78 years vs. 69 years), we also investigated whether age is a determining factor for SH3BP5 levels compared with the presence of AD. As a result, it was found that the SH3BP5 levels of the elderly (over 71 years old) were not significantly lower than those of the younger ones (less than 71 years old) (unpaired T test, p = 0.633) (Figure S6).

[0201] In addition, SH3BP5 levels in tissue lysates from the temporal lobes of autopsied AD patients and non-AD cases were measured using SH3BP5 ELISA (Table 4 and Table S3). As a result, it was found that SH3BP5 levels in the temporal lobes of AD patients were significantly lower than those in non-AD cases (unpaired T test, p = 0.0084) ( Fig.11 d and e, Table 4).

[0202] As a further development, it was found that CLSP1-61, a CLSP derivative, did not bind to ApoE4 (Figure S4a and b). Moreover, since it contains HER, it is likely to maintain CLSP activity. When its cell death inhibitory activity was studied using a cell death assay, the minimum cell death inhibitory concentration was 0.5 nM (Figure L1), which is almost the same as that of wild-type CLSP ( Figure 2 ). When the three CLSP inhibitors were further studied to see whether they could inhibit the activity of CLSP1-61, as expected, even when 10 times the amount of each inhibitor (ApoE4, 14-3-3σ, calreticulin) was added, the activity of CLSP1-61 could not be inhibited (Figure L2). Therefore, it was determined that CLSP1-61 is a CLSP derivative that is not inhibited by inhibitors and maintains activity.

[0203] In addition, it was found that CLSP was bound to the collagen region (ADNCol) of adiponectin (Figure S4c). Therefore, it was studied whether the CLSP activity enhancing effect of adiponectin was sufficient only by ADNCol. As a result, 1nM ADNCol was the same as 1nM wild-type adiponectin, enhancing the activity of 50pM CLSP and completely inhibiting cell death (Figure L3). Further using the same assay, the amount of ADNCol was increased or decreased to study the minimum ADNCol concentration that gave complete cell death inhibition activity to 50pM CLSP. As a result, it was determined that the CLSP enhancing activity was slightly weaker than that of wild-type adiponectin, and the concentration was 0.5nM (Figure L4). Therefore, it was determined that ADNCol was a protein that was slightly weaker than wild-type adiponectin in activity but had almost the same effect.

[0204] [A fusion peptide composed of CLSP1-61 and the collagen homology region of adiponectin has potent AD protective activity]

[0205] Next, two hybrid polypeptides consisting of CLSP1-61 and the collagen homology region of adiponectin, and wild-type CLSP and the collagen homology region of adiponectin (referred to as "CLSPCOL" and "wt-CLSPCOL", respectively) were modulated to study whether they maintain the activities of both CLSP and adiponectin. The regions of the two hybrid polypeptides were linked by peptides encoding Myc tags and HisG tags (composed of 6× histidine and glycine). Compared with CLSP1-61 and wild-type CLSP (Figure L1), CLSPCOL and wt-CLSPCOL have more potent CLSP activity (the minimum concentration of both peptides that completely inhibited neuronal cell death was about 100 pM: Figure L5). The results showed that the functions of CLSP1-61 and wild-type CLSP were not destroyed by the C-terminal bond of the collagen homology region of adiponectin, but rather, the collagen homology region of adiponectin enhanced the functions of CLSP1-61 and wild-type CLSP. Therefore, it is believed that the function of the collagen homology region of adiponectin is not disrupted by the N-terminal linkage of CLSP1-61.

[0206] [CLSPCOL effectively penetrates the blood-brain barrier]

[0207] In mice, 1 hour after intraperitoneal injection of 5nmol of CLSP, the concentration of CLSP in cerebrospinal fluid and serum is about 5nM and 500nM (5). On the other hand, the concentration of adiponectin in human cerebrospinal fluid is 1 / 1000 of the concentration of adiponectin in human serum (30). Therefore, it is studied whether CLSPCOL and wt-CLSPCOL penetrate the blood-brain barrier at a speed equivalent to that of wild-type CLSP in mice. 1 hour after intraperitoneal injection of 10nmol of CLSPCOL, the concentration of CLSPCOL in serum and brain lysate containing interstitial fluid (ISF) is about 305nM and 72nM (Figure L6 and Table 1). On the other hand, the estimated concentration of wt-CLSPCOL in serum and brain lysate containing interstitial fluid 1 hour after injection is about 53nM and 2.1nM. The concentration of wt-CLSPCOL in the brain lysate containing ISF was less than the minimum detection limit (4.5 nM) of the ELISA assay used, so the tentative concentration of 2.1 nM may not be correct, but its concentration is indeed less than 4.5 nM. The concentration of CLSPCOL in the brain lysate is estimated to be about 1 / 4 to 1 / 5 of the concentration in serum, while the concentration of wt-CLSPCOL is estimated to be less than 1 / 10 of the concentration in serum. Therefore, the central nervous system transfer of CLSPCOL is also more effective than that of wt-CLSPCOL. In addition, considering the transfer efficiency of CLSP from serum to cerebrospinal fluid in the published results (5), it is believed that the transfer of CLSPCOL across the blood-brain barrier is much more effective than that of wt-CLSP.

[0208] [CLSPCOL is not blocked by ApoE3 and 14-3-3σ but is slightly blocked by calreticulin]

[0209] When investigating whether CLSPCOL is inhibited by three inhibitors, it was found that although it was not inhibited by ApoE3 and 14-3-3σ at 10-fold higher concentrations, it was unexpectedly slightly inhibited by calreticulin at 10-fold higher concentrations (Figure X1). On the other hand, wt-CLSPCOL was not inhibited by all inhibitors (Figure X2). When the concentration of added calreticulin was changed for detailed investigation, it was found that calreticulin showed inhibitory activity against 100 pM CLSPCOL starting from a concentration of 1 nM (Figure X2).

[0210] [Investigation]

[0211] In neurodegenerative diseases including AD, it is generally accepted that neurodegeneration is caused by increased neurotoxic substances or neurological disorder mechanisms. In AD, the increase in Aβ (aggregated fibrillar Aβ and / or soluble Aβ oligomers in senile plaques) levels is considered to be the main cause of damage over 20 years or longer (2). In addition, the possibility of hyperphosphorylated Tau and neurological disorder mechanisms related to amyloid β precursor protein and presenilin, which are not directly related to the increase in Aβ levels, as toxic involvement has also been shown. In addition, previous studies or this study suggest that in addition to these known neurological disorder mechanisms, the reduction / weakening of AD protective factors may also contribute to the deterioration of AD. Among them, it is speculated that CLSP is likely to play a core role as this AD protective (defense) factor (6).

[0212] Human peptides and CLSP inhibit AD-related neuronal cell death in vitro (5, 6). In addition, CLSP inhibited synaptic loss and memory impairment in AD model mice (8) regardless of Aβ regulation. The latter result is also supported by a series of previous studies (25-27). That is, this is a study in which a potent derivative of a human peptide, which is an alternative agonist of htHNR, inhibited memory impairment in AD model mice. Based on these results, the inventors proposed a hypothesis about the etiology of AD: two phenomena, namely, an increase in AD-related neurotoxicity and a decrease in AD protective activity, are necessary for the onset of AD. If this hypothesis is considered correct, in the presence of sufficient concentrations of active CLSP, even if AD-related neurotoxicity is sufficiently enhanced, neuronal cell death (and dysfunction) cannot be caused, and therefore AD will not develop. In addition, in the absence of sufficient AD-related neurotoxicity, even if the CLSP effect is reduced, neuronal cell death (and dysfunction) will not be caused (i.e., AD will not develop). In the data shown in this study, in addition to almost all AD cases, there are several "non-AD" controls with reduced levels of adiponectin and SH3BP5 in the CNS ( Fig.10 and 11 ), the experimental results show that these ideas are extremely appropriate.

[0213] CLSP is considered to be a core AD protective factor (5, 6 and 8) that binds to the heterotrimeric human peptide receptor and activates the STAT3-induced survival signaling pathway, and its abnormal regulation is likely to contribute to the etiology of AD. Among the multiple CLSP inhibitors identified by the present invention, ApoE is considered to be a core inhibitor in terms of concentration and activity ( Figure 2 ). It is speculated that the concentration of total ApoE in the human CNS is absolutely higher than that of CLSP (18-20)(14). Therefore, if the in vivo CLSP activity regulation model consisting only of CLSP and a very large amount of CLSP inhibitors is correct, there is a high possibility that the AD protective activity in vivo is almost zero.

[0214] However, as shown in the present invention, if adiponectin enhances CLSP activity by binding to the endogenous human peptide homology region (EHR) of CLSP, thereby preferentially protecting CLSP from the effects of CLSP inhibitors ( Figures 5 to 7 ), the CLSP activity in vivo will be guaranteed regardless of the high concentration of the inhibitory substance. Even in the presence of much higher concentrations of CLSP inhibitors, 0.2-0.25 nM adiponectin can fully maintain 1 nM CLSP activity ( Figure 5 and 7 In the absence of AD, the adiponectin concentration in CSF is 0.96 ± 0.19 nM ( Fig.10 and Table 1), and as a result, the possibility of maintaining CLSP activity was high.

[0215] Adiponectin plays a variety of metabolic functions in peripheral tissues, including glucose and lipid metabolism (28). It may increase insulin signaling, anti-inflammatory, antioxidant, and anti-atherogenic functions through two common adiponectin receptors on the cell membrane. The movement of adiponectin across the blood-brain barrier is believed to be very limited. The concentration of adiponectin in CSF is almost 10% lower than that in serum. 3 times (29, 30). Considering the presence of common adiponectin receptors in the CNS, it is assumed that adiponectin acts as a regulator of glucose metabolism and a promoter of neurogenesis in the CNS, and further acts as a protective factor against ischemic brain damage, for example (31). A large number of studies have provided evidence that adiponectin deficiency or abnormal regulation of adiponectin signaling is associated with the onset of AD (31). Increased serum adiponectin levels (29, 30) may be an independent risk factor for AD (32). On the other hand, a study showed that AD-like symptoms were significantly more common in type II diabetic patients with low serum adiponectin concentrations (33). Adiponectin levels are downregulated in the CSF of AD patients, which is inversely correlated with increased Aβ levels (30). Adiponectin knockout mice show AD-like symptoms (34).

[0216] The present invention shows that the concentration of adiponectin in the CSF of AD patients is reduced ( Fig.10 ). This result is consistent with the previous report (30). Considering that the protein concentration in CSF is correlated with the concentration in the interstitial fluid of the brain (36), these results suggest that the concentration of adiponectin in the interstitial fluid of AD brains is reduced, and CLSP activity may not be maintained. As actual data, the mean ± SEM concentration of CSF adiponectin in AD patients was 0.31 ± 0.13 nM, while the value in non-AD cases was 0.96 ± 0.19 nM (unpaired T test, p = 0.0065) ( Fig.10 and Table 1). Figure 5 and 7 As shown in Figure 2, it is speculated that the minimum concentration of adiponectin in the perineural local area required to fully maintain CLSP activity is 0.20-0.25 nM, which is close to the average CSF adiponectin concentration in AD patients, which has been reduced. Although there is sufficient adiponectin in the perineural local area of ​​non-AD, it suggests that the amount of adiponectin at this site may be insufficient in AD. As further data supporting this idea, it was found that the level of SH3BP5, which is the main mediator of human peptide / CLSP signaling in neurons, was reduced in AD cortex ( Fig.11 ). As similar data, previous studies have shown that the level of STAT3, which is an active form of STAT3 activated by human peptide / CLSP signals and has phosphorylated tyrosine at position 705, is reduced in hippocampal neurons of AD patients (35). It should be noted that this shows that human peptides and CLSPs bind to htHNRs and activate intraneuronal signaling mediated by STAT3 (6) and SH3BP5 (24), thereby acting as an AD protective factor.

[0217] Previous studies have also shown that adiponectin is elevated in the serum of AD patients (29, 30) and decreased in the AD brain ( Fig.10 , and Tables 1 and 2) (30). One explanation for this observation is the idea that adiponectin levels decrease due to one or more AD-related abnormalities occurring in the central nervous system, and then in order to restore its deficiency, the production of adiponectin in adipose tissue increases secondary, resulting in an increase in serum. In fact, previous studies have suggested that adiponectin may be reduced in the central nervous system of AD patients because it is fixed in aggregates of neurofibrillary aggregates containing hyperphosphorylated Tau within the nerves (30). If this idea is correct, the increase in Aβ and the accumulation of hyperphosphorylated Tau as its downstream target are the main reasons for the decrease in adiponectin levels in AD. On the other hand, it is also believed that the decrease in adiponectin levels in the central nervous system is caused by impaired blood-brain barrier transport of adiponectin in AD. So far, a lot of evidence has been shown to show that the function of the blood-brain barrier in the brain of AD is impaired (37), but since there is no data on the blood-brain barrier transport of adiponectin, it is not clear which idea is correct.

[0218] ApoE4 is a major risk factor for AD. So far, through a large number of studies, the mechanism of increased AD incidence caused by ApoE4 has been widely studied. It is believed that ApoE4 exerts neurotoxicity through a variety of gain-of-function and loss-of-function mechanisms in both Aβ-dependent and -independent modes (38). Among them, the following studies are well known: the production of Aβ, the clearance of Aβ from the central nervous system, and the aggregation formation of Aβ are affected by intracellular information mediated by ApoE receptors, and these phenomena tend to lead to AD in ApoE4 holders.

[0219] The present invention shows that ApoE4 is a slightly stronger CLSP inhibitor than ApoE3 ( Figure 2 b and c). Considering that the concentration of ApoE in the CNS is very high compared to the concentration of CLSP, the slight difference is meaningless, and ApoE3 and ApoE4 are likely to reduce CLSP activity in the same way. However, if it is considered that only free ApoE that is not lipidated (or not mobilized into high-density lipoprotein-like lipid particles) can inhibit CLSP, then assuming that the concentration of non-lipidated ApoE is at the same level as the concentration of CLSP, in a state where the level of adiponectin is reduced (AD patients), the slight difference in the CLSP inhibitory effect of ApoE may become a decisive factor in affecting the onset of the disease. In this case, since ApoE4 inhibits CLSP activity more strongly ( Figure 2 b and c), so ApoE4 gene carriers are more susceptible to AD damage than non-ApoE4 carriers. Unfortunately, a specific method for quantifying the amount of non-lipidated ApoE, which should be carried out to study the validity of this idea, has not yet been found.

[0220] In the present invention, based on the knowledge that the level of adiponectin is reduced in the CSF of AD patients and that the level is close to the limit level (0.3 nM) that can protect CLSP ( Fig.10 and Tables 1 and 2), and the levels of SH3BP5 and activated STAT3 were decreased in AD brain ( Fig.11 )(35) speculated that CLSP signaling in neurons is decreased in AD brain.

[0221] However, in the present invention, since it is technically almost impossible to measure the adiponectin concentration in the interstitial fluid surrounding AD brain nerve cells, the concentration in CSF, which has a similar concentration, was measured to study the phenomenon in the interstitial fluid.

[0222] Moreover, in the present invention, it is technically impossible to directly show that the CLSP induction signal in the neuron is reduced in the AD brain, so it is indirectly shown. SH3BP5 and STAT3 are regulated simultaneously by the signal transduction pathway caused by the physiologically active substances with various cytokines as the core, so the reduction of SH3BP5 levels and the inactivation of STAT3 can be caused, and the CLSP induction signal transmission will not be reduced. Therefore, it is impossible to conclude that the reduction of CLSP induction signals is caused by the reduction of both. However, it is generally known that inflammation occurs in the CNS of AD, and various inflammatory cytokines are produced as a result. Moreover, the effect of the various inflammatory cytokines that rise is to increase the level of activated STAT3 and SH3BP5 (downstream target of STAT3) in neurons. Therefore, when the levels of activated STAT3 and SH3BP5 in the neurons of AD are lower than normal, it is considered that there is a rising mechanism caused by various inflammatory cytokines released to the surroundings, and it is considered that the reduction of activated STAT3 and SH3BP5 shows that the idea of ​​reducing CLSP induction signals is appropriate.

[0223] [CLSPCOL]

[0224] CLSPCOL is not inhibited by CLSP inhibitors and has potent AD protective activity (Figure L5). Moreover, the collagen homology region (COL) of adiponectin maintains the activity of enhancing and protecting endogenous wild-type CLSP. Moreover, CLSPCOL effectively penetrates the blood-brain barrier (Figure L6). Therefore, the fusion proteins of the present invention such as CLSPCOL do not have the currently identified weaknesses and can be used as AD drug candidates that can be delivered via peripheral routes.

[0225] However, the mechanism by which CLSPCOL is more efficient than wt-CLSPCOL and CLSP in penetrating the blood-brain barrier has not been fully elucidated. Since there is a clear difference in efficiency between CLSPCOL and wt-CLSPCOL (Figure L6 and Table L1), it is likely that the deletion of the C-terminal domain (amino acids 62-146) of CLSP promotes efficiency. That is, the C-terminal half of CLSP may contain a region that hinders blood-brain barrier transfer. In addition, it is also possible that the efficiency is improved by the attachment of the collagen homology region of adiponectin.

[0226] CLSPCOL is only slightly inhibited by calreticulin among the inhibitory substances (Figures X1 and X2). The specific mechanism is not clear, but it is speculated that the region containing the artificially produced fusion part may have affinity for calreticulin. However, the inhibitory effect is expected to be weak, and the concentration of calreticulin in the central nervous system is lower than the concentration that shows the inhibitory effect (less than 1nM), so it is believed that it will not be an obstacle in actual clinical application.

[0227] The materials and methods used in the above examples are as follows. It should be noted that, unless otherwise specified, the above examples were implemented using appropriate methods / means known to those skilled in the art.

[0228] [Gene and vector]

[0229] Human CLSP was inserted into pcDNA3.1-MycHis (Invitrogen, Carlsbad, CA) to express human CLSP-MycHis (CLSP-MycHis) tagged with MycHis at the C-terminus in mammalian cells (5). Human apolipoprotein E3, E4, adiponectin, annexin II, and annexin V cDNAs were inserted into a CMV promoter-driven expression vector, pHA vector, which has a hemagglutinin A (HA) tag at the C-terminus. Mouse V642I-APP cDNA inserted into the pcDNA3.1 / MycHis vector is described in the prior art (5). Apolipoprotein E3, E4, and adiponectin cDNAs were inserted into the pFLAG vector and used as a protein expression vector with a FLAG tag at the C-terminus.

[0230] As described in the literature (5), the recombinant protein with Schistosoma japonicum glutathione S-transferase (GST) tag was produced in bacteria using the pGEX vector (Promega, Madison, WI). In the production of the C-terminal HiBiT tag CLSP, an oligonucleotide encoding the HiBiT amino acid sequence (VSGWRLFKKIS) and a sense primer (SEQ ID NO: 4) were added:

[0231] (5'-CCCGGGGTGAGCGGCTGGCGGCTGTTCAAGAAGATTAGCTGAGAATTC-3'), and antisense primer (SEQ ID NO: 5):

[0232] (5'-CCCGGGGTGAGCGGCTGGCGGCTGTTCAAGAAGATTAGCTGAGAATTC-3')

[0233] After in vitro annealing, the fragment was inserted into the SmaI-EcoRI site of the pGEX-2T-CLSP plasmid.

[0234] The full-length human adiponectin cDNA in the pCMV-SPORT6 vector was purchased from Invitrogen (Catalog No. 6192794, CA). In order to prepare a recombinant N-terminally GST-tagged protein tagged with MycHisG at the C-terminus, the sequence of the pGEX2T-MycHis vector was mutated using the KOD-Plus mutagenesis kit (SMK-101 Tokyo, Toyobo, Japan, Catalog No.) using the following mutagenesis primers to generate a glycine residue added to the C-terminus.

[0235] Sense primer (SEQ ID NO:6):

[0236] (5'-GGTTGAGAATTCATCGTGACTGACTGACGATCTGCCTCGCGCG-3'), and antisense primer (SEQ ID NO: 7):

[0237] (5'-ATGATGATGATGATGATGATCCTCTTCTGAGATGAGTTTTTG-3').

[0238] The cDNA of the collagen homology region of human adiponectin was amplified by KOD DNA polymerase (KOD-101, TOYOBO, Tokyo, Japan, catalog number).

[0239] Sense primer (SEQ ID NO: 8):

[0240] (5'-GGATCCATGAGAGGATCGCATCACCATCACCATCACGGGTCC-3'), and antisense primer (SEQ ID NO: 9):

[0241] (5'-GAATTCTCAAGGTTCTCCTTTCCTGCCTTGGATTCCCGGAAAGC-3').

[0242] The amplified cDNA was subcloned into pQE30 vector (QIAGEN, Tokyo, Japan) at the BamHI-EcoRI site.

[0243] The cDNA of the collagen homology region of adiponectin having a MycHisG tag at the N-terminus was amplified by LA Taq polymerase (TaKaRa, catalog number RR002A, Tokyo, Japan).

[0244] Sense primer (SEQ ID NO: 10):

[0245] (5'-AAGCTTGAACAAAAACTCATCTCAGAAGAGGATCATCATCATCATCAT CATGGTATGGGGCATCCGGGCCATAATGGGGCCCCAGGCC-3'), and

[0246] Antisense primer (SEQ ID NO: 11):

[0247] (5'-GAATTCTCAAGGTTCTCCTTTCCTGCCTTGGATTCCCGGAAAGCC-3').

[0248] The amplified cDNA was subcloned into pGEX-2T-CLSP and -CLSP(1-61) plasmids to obtain wt-CLSPCOL and CLSPCOL consisting of the collagen homology region of CLSP-MycHisG-adiponectin and the collagen homology region of CLSP(1-61)-MycHisG-adiponectin, respectively.

[0249] [Recombinant protein]

[0250] GST-human CLSP (GST-CLSP-MycHis) tagged with MycHis at the C-terminus was expressed in E. coli BL-21 in 1 mM isopropyl-thio-β-D-galactopyranoside at 37°C for 6 hours. GST-CLSP-MycHis was bound to glutathione Sepharose (GE Healthcare) and the CLSP-MycHis moiety was released from glutathione Sepharose overnight at 25°C by incubation in PBS containing 1 unit / ml of thrombin as described in the literature (14) (Catalog number: T6634-100UN, Sigma-Aldrich, St. Lois, MO). Recombinant CLSP deletion mutants (5) tagged with MycHis at the C-terminus and GST-CLSP-HiBiT were prepared in the same manner. Recombinant annexin II, annexin V and SH3BP5 proteins were also prepared from GST-annexin II, annexin V and SH3BP5 produced in bacteria. Recombinant GST-MycHis and GST-human 14-3-3σ were expressed in E. coli BL-21 in 1 mM isopropyl-β-D-thiogalactopyranoside at 37°C for 6 hours, bound to glutathione Sepharose, released from glutathione Sepharose by co-incubation in the presence of 50 mM glutathione, and dialyzed against PBS. The collagen homology region of adiponectin with a 6×HisG tag at the N-terminus was expressed in E. coli M15 [pREP4] (Qiagen) in 1 mM isopropyl-β-D-thiogalactopyranoside at 37°C for 4 hours, bound to Talon Metal resin (Clontech, Palo Alto, CA, USA), and purified according to the manufacturer's instructions. The eluted recombinant 6×His protein was desalted by Zeba desalting column (Pierce), and then 1 / 10 volume of 10×PBS was added to the desalted protein solution.

[0251] Recombinant human apolipoprotein E3 and apolipoprotein E4 were purchased from PeproTech (Rocky Hill, NJ) (Catalog Nos. 350-02 and 350-04). Human adiponectin and trimeric adiponectin were purchased from BioVendor (Czeck Republic) (Catalog Nos. RD172029100 and RD172023100).

[0252] [Cell death assay]

[0253] The neuronal cell death assay for AD was first performed by Yamatsuji et al. (39). SH-SY5Y cells were grown in a DMEM / HamF12 mixture (DMEM / F12) containing 10% FBS. SH-SY5Y cells were plated at 2×10 5 / well was inoculated on a 6-well plate for 12 to 16 hours, transfected with the indicated vector for 3 hours in the absence of serum, and then cultured in DMEM / F12-10% FBS containing / without CLSP and / or CLSP modifying substances (substances that act on CLSP). 24 hours after transfection, the culture medium was exchanged for DMEM / F12 containing / without CLSP and / or CLSP modifying substances and containing N2 supplement (Invitrogen, Carlsbad, CA). Cells were recovered 48 hours after the start of transfection and cell survival (rate) was determined using a WST-8 cell death assay kit (Dojindo, Kumamoto, Japan) or stained with calcein AM (Dojindo, Kumamoto, Japan), and a trypan blue exclusion cell death assay. The transfection efficiency in SH-SY5Y cells was approximately 80%. All cell death experiments were performed with N=3.

[0254] [Antibody]

[0255] Rabbit polyclonal antibodies were generated against a peptide of 16 amino acids at the N-terminal end of human CLSP that forms a complex with keyhole limpet hemocyanin and affinity purified using the immunizing peptide (hCLSP-N antibody). Rabbit polyclonal antibodies against GST-CLSP-MycHis were generated by immunizing with recombinant GST-CLSP-MycHis (GST-CLSP antibody) (5) produced in bacteria. The antibodies were then affinity purified from crude serum in which recombinant CLSP-MycHis was used. Affinity purification was performed using 14-3-3σ. Sigma-C antibodies were generated by immunizing rabbits with a C-terminal 16 amino acid peptide of human 14-3-3σ and affinity purified. Polyclonal antibodies against SH3BP5 (designated "SH3BP5 antibody") were generated in rabbits and affinity purified using GST-14-3-3σ and GST-SH3BP5, and then affinity purified using GST-SH3BP5.

[0256] Ready-made antibodies against peptides and proteins used in the present invention were purchased from the following companies: FLAG epitope conjugated with horseradish peroxidase (clone M2, catalog number 158592-1MG), Sigma-Aldrich; APP (22C11, catalog number MAB348 (registered trademark)), Chemicon (Temecula, CA); Myc epitope (catalog number R950-25), Invitrogen (Carlsbad, CA); HA (hemagglutinin A) epitope conjugated with peroxidase (Chemicon, Inc., San Diego, CA); 3F10, catalog number 2013819), Roche Diagnostics (Alameda, CA); SH3BP5 antibody (Sab; catalog number sc-135617), Biotechnology (Santa Cruz, CA); SH3BP5 monoclonal antibody (clone 1D5, catalog number H00009467-M02), Abnoba; HisG monoclonal antibody (catalog number R940-25), Invitrogen (Carlsbad, CA).

[0257] [Western blot analysis]

[0258] The cells were washed twice with PBS and suspended in 50 mM HEPES (pH 7.4), 150 mM NaCl, 0.1% NP-40, and a protease inhibitor cocktail cOmplete (Roche Diagnostics, Alameda, CA). After two freeze-thaw cycles, the cell lysates were centrifuged at 15,000 rpm for 10 min at 4°C. The supernatants and pull-down pellets were subjected to standard or Tris-Tricine SDS polyacrylamide gel electrophoresis (SDS-PAGE)-based analysis and immunoblotting analysis. 10 μg of cell lysate was used directly for immunoblotting analysis in each lane (5). Endogenous wild-type APP of various lengths was simultaneously detected by immunoblotting analysis using APP antibodies to detect exogenously expressed V642I-APP. It should be noted that for unknown reasons, the detection of endogenous wild-type APP of various lengths was uneven between different experiments.

[0259] [Pull-down analysis]

[0260] The binding of recombinant protein to cyanogen bromide activated Sepharose 4B was performed according to the instructions of the manufacturer (Amersham Pharmacia Biotech, Uppsala, Sweden). Briefly described as follows: 5 mg of recombinant protein was rotated together with 3 ml of cyanogen bromide activated Sepharose 4B in coupling buffer (0.1 M NaHCO3 containing 0.5 M NaCl, pH 8.3) and incubated at 4°C overnight. Next, the Sepharose bound to the recombinant protein was incubated in blocking buffer (0.2 M glycine, pH 8.0) at room temperature for 2 hours to exclude nonspecific binding. After blocking, the Sepharose was washed with coupling buffer and 0.1 M sodium acetate buffer (pH 4) containing 0.5 M NaCl. The bound Sepharose 4B was stored in coupling buffer at 4°C.

[0261] Lysates from cells overexpressing various proteins were mixed with Sepharose 4B bound to GST-MycHis or CLSP-MycHis at 4°C overnight and then washed thoroughly. Pull-down precipitates and cell lysates were then subjected to SDS-PAGE and immunoblot analysis or silver staining (Wako Pure Chemical Industries, Ltd., Tokyo, Japan) to investigate the binding between CLSP and proteins.

[0262] In the experiment, recombinant CLSP tagged with MycHis at the C-terminus, one of its deletion mutants (ΔN1, ΔN2, ΔC1 and EHR) was produced in bacteria and purified. They were mixed with lysates from F11 cells containing apolipoprotein E4 or adiponectin tagged with FLAG at the C-terminus at 4°C overnight and then washed thoroughly. The washed pull-down precipitate and cell lysate were then developed by SDS-PAGE and analyzed by immunoblotting.

[0263] [Preparation of mouse-derived brain lysate as a brain sample containing interstitial fluid after intraperitoneal injection of recombinant protein]

[0264] All experimental procedures were approved by the Regional Committee for Animal Experimentation of Tokyo Medical University. Female ICR mice (8 weeks old) purchased from Oriental Yeast (Tokyo, Japan) were intraperitoneally injected with 10 nmol of GST-MycHisG protein, CLSPCOL or wt-CLSPCOL in PBS as a negative control. One hour after the injection, the mice were anesthetized with diethyl ether (Wako Pure Chemical Industries, Ltd., Tokyo, Japan). After that, blood was drawn from the heart and centrifuged at 4000×g for 10 minutes at 4°C. Using 20 ml of lactated Ringer's solution (Otsuka Pharmaceutical, Tokyo, Japan) with ice added, the vascular space of the brain was perfused through the left ventricle of the heart to remove blood. Next, the mouse was dislocated and the brain was removed. In order to wash away CSF contamination, the whole brain was washed once with lactated Ringer's solution. Then, homogenization was performed in the presence of 2 times the weight of saline. The lysate was centrifuged at 4000×g for 10 minutes at 4°C, and the supernatant was recovered as a brain sample containing interstitial fluid ( 36 ).

[0265] [Human cerebrospinal fluid and temporal lobe samples]

[0266] Postmortem CSF and temporal lobe samples from AD patients and controls were obtained from the Kathleen Price Bryan Brain Bank, Department of Neurology, Duke University Medical Center (Tables 1 and 3). Pathological staging of senile plaques and neuritic plaques was performed under the "Combined Registry for AD" (CERAD) staging system (40), while pathological staging of neurofibrillary changes (tangles) was performed under the Braak staging system (41). Cases considered as possible AD according to the CERAD staging were counted as AD cases. This study was approved by the Kathleen Price Bryan Brain Bank, Duke University Medical Center and the Ethics Committee of Tokyo Medical University.

[0267] [Determination of dissociation constant]

[0268] The dissociation constant for the binding between apolipoprotein E4 (or adiponectin) and CLSP was determined using the Nano-Glo HiBiT extracellular detection system (Promega, catalog number: N2420) according to the instructions. To encode recombinant apolipoprotein E4 or adiponectin, 100 μl of 50 mM carbonate buffer (pH 9.6) containing 20 pM apolipoprotein E4 or adiponectin was incubated overnight at 4° C. in the wells of a 96-well plate (black fluorescent plate H catalog number: MS-8596KZ, Sumitomo Bakelite, Tokyo, Japan). The protein-coated plate was washed three times with 200 μl of PBS. Next, 150 μl of PBS (GIBCO) containing 1% skim milk was added to each well. They were incubated at room temperature for 1 hour without shaking. After the plate was washed three times with 200 μl of PBS, a PBS solution of CLSP-HiBiT at a concentration of 100 μl was added to each well. The plate was incubated at 4°C overnight without shaking, and then washed five times with PBS containing 0.1% NP-40, followed by the addition of 100 μl of PBS. The HiBiT substrate in the kit was then added to each well. TM The chemiluminescence obtained in each well was measured by X5 (Perkin Elmer). The CLSP-HiBiT concentration in each well was estimated by measuring the chemiluminescence of the wells filled with 100 μL PBS containing CLSP-HiBiT at stepwise increasing concentrations and referring to the prepared standard curve. This experiment was performed with N=2.

[0269] [ELISA]

[0270] Ready-made human adiponectin ELISA kits were purchased from Sekisui Medical Co., Ltd. (Cat. No. 376405, Tokyo, Japan) and used to measure CSF adiponectin concentrations according to the manufacturer's instructions. In the case of 14-3-3σ ELISA and SH3BP5, 100 μL of 50 mM carbonate buffer (pH 9.6) containing 0.6 μg / ml of GST sigma antibody or 1 μg / ml of SH3BP5 monoclonal antibody (clone 1D5, Cat. No. H00009467-M02, Anoba) was incubated overnight at 4°C in a 96-well plate (ELISA plate H, Cat. No. MS-8896FZ, Sumitomo Bakelite, Tokyo, Japan). The capture antibody-coated plate was washed three times with 400 μl of washing buffer (PBS containing 0.1% NP40) in each well, and then filled with 300 μl of PVDF blocking reagent (TOYOBO catalog number NYPBR01, Tokyo, Japan) at room temperature for 1 hour without shaking. After washing three times with 300 μl of washing buffer, the plate was filled with 100 μl of PBS solution of recombinant 14-3-3σ or SH3BP5 with step-by-step concentration increase (for determining the standard curve). Human CSF samples or human temporal lobe lysates were incubated at room temperature for 2 hours while shaking at 250 rpm. Thereafter, the plate was washed with 300 μl of washing buffer. As detection antibodies, peroxidase-labeled sigma-C antibody or SH3BP5 antibody were prepared using Ab-10 Rapid Peroxidase Labeling Kit (Dojindo, catalog number LK33, Kumamoto, Japan) or Peroxidase Labeling Kit-HN2 (Dojindo, catalog number LK11, Kumamoto), respectively. 100 μl of 1.0 μg / ml of detection antibody Can Get Signal Solution 2 (TOYOBO catalog number NKB-301) was added to each well and incubated at room temperature for 1 hour while shaking the plate at 250 rpm. After washing 5 times with 300 μl of wash buffer, R&D TMB substrate solution (R&D Systems, catalog number: DY999) was added to the wells and the plate was incubated at room temperature for 10 minutes. The reaction was terminated by adding 50 μl of H2SO4. Using WallacARVO TM X5 (Perkin Elmer) was used to measure the absorbance at 450 nm.

[0271] Biotin-labeled anti-HisG antibody was prepared using Biotin Labeling Kit-NH2 (Dojindo, catalog number: LK03, Kumamoto, Japan) according to the manufacturer's instructions. In the case of ELISA of CLSPCOL and wt-CLSPCOL (containing Myc and HisG tags as binding peptides in sequence), 100 μl of 50 mM carbonate buffer (pH 9.6) containing 25 μg / ml of CLSP-N antibody (capture antibody) was incubated overnight at 4°C in a 96-well plate (ELISA plate H, catalog number MS-8896FZ, Sumitomo Bakelite, Tokyo, Japan). The capture antibody-coated plate was washed three times with 400 μl of washing buffer (PBS containing 0.1% Tween 20) per well, and then filled with 300 μl of PVDF blocking reagent (TOYOBO catalog number NYPBR01, Tokyo, Japan) and kept at room temperature for 1 hour without shaking. After washing 3 times with 300 μl of washing buffer, fill the plate with 100 μl of PBS (for determining the standard curve) or mouse brain lysate containing GST-MycHis, CLSPCOL and wt-CLSPCOL with increasing concentrations in stages, and incubate at room temperature for 2 hours. After washing with 300 μl of washing buffer, fill the plate with 100 μl of 1000-fold diluted biotin-conjugated anti-HisG antibody Can Get Signal solution 1 (TOYOBO catalog number: NKB-201) and incubate. Incubate at room temperature for 1 hour. Next, wash the plate 3 times with 300 μl of washing buffer. Next, fill the plate with 100 μl of 2000-fold diluted streptavidin-conjugated HRP (Invitrogen) Can Get Signal solution 2 (TOYOBO catalog number: NKB-301) and incubate at room temperature for 1 hour. After washing five times with 300 μl of washing buffer, the plate was filled with 100 μl of R&D™ B substrate solution (R&D Systems, catalog number: DY999) and incubated at room temperature for 3 minutes. The reaction was terminated by adding 50 μl of H2SO4. The absorbance at 450 nm was measured using Wallac ARVOTMX5 (Perkin Elmer).

[0272] [Immunohistochemical analysis of human samples]

[0273] This study was approved by the Ethics Committee of Tokyo Medical University. Histological brain samples were obtained at Gunma Geriatric Research Hospital according to established procedures after informed consent was obtained from the family members of each patient. The patients were diagnosed with AD according to clinical criteria, and the diagnosis was confirmed by neuropathological analysis under autopsy. At autopsy, the brain was fixed with 4% paraformaldehyde in PBS solution (pH 7.4), embedded in paraffin, and then subjected to neuropathological examination. The cerebral cortex and hippocampus used in this study were obtained from samples of 6 patients with sporadic (episodic) AD and 5 patients with a representative motor neuron-specific neurodegenerative disease, sporadic amyotrophic lateral sclerosis (ALS).

[0274] The sections were deparaffinized, rehydrated with PBS, and then unmasked for 15 minutes in Antigenunmasking solution (Vector Laboratories, Burlingame, CA). The sections were then incubated in blocking solution containing goat normal serum and 0.3% Triton X-100 in TBS for 20 minutes at room temperature and then incubated with 5 μg / ml mouse IgG1 (R&D Systems catalog number MAB002, Minneapolis, MN) or SH3BP5 (Sab) monoclonal antibody clone PL-A23 (Santa Cruz Biotechnology, catalog number sc-135617, Santa Cruz, CA) as a negative control for 3 nights at 4°C in PBS containing 1% BSA. Immunoreactivity was visualized using the TSA (Tyramide signal amplification)-enhanced fluorescein system (Perkin-Elmer, Waltham, MA) (Tyramide-Red method). Fluorescently labeled samples were observed under a fluorescence microscope (Biozero, KEYENCE, Osaka, Japan). Fluorescent images were analyzed using NIH ImageJ1.37v.

[0275] [Quantification of SH3BP5 immunofluorescence intensity in neurons]

[0276] NIH Image 1.37v was used to quantify the SH3BP5 immunofluorescence intensity and the area of ​​the selected neurons. 2 The average SH3BP5 immunofluorescence intensity of neurons (a). The 1 μm surrounding neurons was also quantified. 2 The average immunofluorescence intensity of the neuropil was used as the background immunofluorescence (b). The average immunofluorescence intensity (ab) subtracted was used as the average SH3BP5 immunofluorescence intensity of the neuron. Then, the level of SH3BP5 expression in the neuron was inferred by multiplying the neuron area by the ab value. Ten neurons were randomly selected and the average immunofluorescence intensity in the ten neurons of each sample was calculated for each sample.

[0277] [Statistical Analysis]

[0278] All data were analyzed using Prism7 for Mac OSX software (GraphPad, San Diego, USA). Data in cell death experiments are expressed as mean ± standard deviation. All other data are expressed as mean ± SEM. Unpaired T test (two-sided) was used in the analysis of data obtained from histological experiments and ELISA experiments.

[0279] [Table 1]

[0280] Analysis of data from 34 autopsy subjects with measured CSF adiponectin concentrations

[0281]

[0282] PMD: time after death until autopsy;

[0283] *P<0.0001 when "greater than (>)" before age was regarded as "equal to". See "Age" in Table S1.

[0284] [Table 2]

[0285] Data analysis of 11 cases aged 81 to 88 years selected from Table 1

[0286]

[0287] PMD: time since death until autopsy.

[0288] [Table 3]

[0289] Analysis of data from 13 postmortem subjects in whom SH3BP5 levels were measured in neurons of the outer pyramidal layer of the temporal or occipital lobes

[0290] [Table 4]

[0291] Analysis of data from 20 postmortem subjects in whom SH3BP5 levels in cell lysates from the temporal lobe were measured

[0292] PMD: time after death until autopsy;

[0293] * When "greater than (>)" before age was regarded as "equal to", p<0.876. See "Age" in Table S3.

[0294] Since the p value was less than 0.05 (0.032), for age analysis, unpaired T test with Welch correction was used.

[0295] [Table 5]

[0296] [Table S1-1]

[0297] Individual data from autopsy cases where CSF adiponectin levels have been examined

[0298] age gender ApoE PMD CERAD stage or diagnosis B&B Stage 81 M 34 7.2 Normal CERAD1B I 90 M 33 7.4 Normal CERAD1A II 88 M 23 17.3 Normal CERAD1A I 86 M 34 6.1 Normal CERAD1A III 90 M 33 4.0 Normal CERAD1B II 86 M 33 16.3 Normal CERAD1A I >90 M 34 7.7 Normal CERAD1B I >90 M 33 22.3 Normal CERAD1A III 90 M 23 3.7 Normal CERAD1A III >90 F 23 5.0 Normal CERAD1B II 72 F 33 30.0 Normal CERAD1B II >90 F 23 5.2 Normal CERAD1B III 85 F 33 13.0 Normal CERAD1A II 80 F 33 16 Normal CERAD1A III 73 M 33 9.4 Possible AD III 79 M 24 6.5 Possible AD III

[0299] [Table 6]

[0300] [Table S1-2]

[0301] Individual data from autopsy cases where CSF adiponectin levels have been examined

[0302]

[0303]

[0304] ApoE: The names of the 2 apolipoprotein E alleles are represented by numbers;

[0305] PMD: time after death until autopsy, B&B stage: Braak&Braak stage;

[0306] The 2 possible AD cases were counted as AD cases.

[0307] The mean ± SEM age of all AD cases and non-AD cases was greater than 78.5 ± 0.9 years and 86.3 ± 1.4 years, respectively (unpaired T test, p < 0.0001 when "greater than" before age was considered as "equal to"). The mean ± SEM PMD of all AD cases and non-AD cases was 11.7 ± 1.8 hours and 11.5 ± 2.1 hours, respectively (unpaired T test, p = 0.96).

[0308] [Table 7]

[0309] [Table S2]

[0310] Individual data from autopsy cases where SH3BP5 levels were measured in neurons of the outer pyramidal layer of the temporal or occipital lobes

[0311] Sections of the external pyramidal layer of the temporal or occipital lobes were obtained from autopsied AD and ALS patients. CDR: Clinical Dementia Rating, NE: Not Examined.

[0312] The mean ± SEM age of all ALS patients and AD patients was 66.7 ± 2.8 and 75.9 ± 5.1 years, respectively (unpaired T test, p = 0.158).

[0313] [Table 8]

[0314] [Table S3]

[0315] Individual data from autopsy cases where SH3BP5 levels were measured in cell lysates of the temporal lobe

[0316] age gender ApoE PMD CERAD stage or diagnosis B&B Stage >89 F 23 5.0 Normal CERAD 1B II 78 F 33 33.0 Normal CERAD 1A I 82 F 33 15.5 Normal CERAD 1B I 67 F 33 8.0 Normal CERAD 1B I 65 F 33 13.6 Normal CERAD 1A I 72 F 33 30.0 Normal CERAD 1B II 88 F 23 20.5 Normal CERAD 1A I 84 F 33 23.0 Normal CERAD 1B I >89 F 23 5.2 Normal CERAD 1B III 85 F 33 13.0 Normal CERAD 1A II 79 F 44 16.2 AD V 77 F 34 6.0 AD V 80 F 33 5.2 AD V 79 F 44 8.0 AD V 77 F 23 35.4 AD V 81 F 44 14.7 AD V 84 F 34 5.9 AD V 75 F 34 5.9 AD V 74 F 44 20.7 AD V 88 F 34 8.7 AD V

[0317] ApoE: The names of the 2 apolipoprotein E alleles are represented by numbers;

[0318] PMD: time after death until autopsy, B&B stage: Braak&Braak stage.

[0319] The mean ± SEM age of all AD cases and non-AD cases was greater than 79.9 ± 2.9 years and 79.4 ± 1.3 years, respectively (unpaired T test, p < 0.876 when "greater than" before age was considered as "equal to"). The mean ± SEM PMD of all AD cases and non-AD cases was 12.7 ± 3.0 hours and 16.7 ± 3.1 hours, respectively (unpaired T test, p = 0.368).

[0320] [Table 9]

[0321] [Table L1]

[0322] ELISA data of CLSPCOL and wt-CLSPCOL in brain lysate and serum containing interstitial fluid

[0323] A standard dose-response curve was prepared by measuring the recombinant proteins with step-wise increasing concentrations (N=3). In the determination of the concentration of CLSPCOL or wt-CLSPCOL in brain lysate and serum containing ISF, ELISA was performed on 90μL PBS containing 10μL of brain lysate containing interstitial fluid (×10ISF lysate) or 98μL PBS containing 2μL serum (serum×50) (N=3). The measured values ​​for the standard recombinant proteins with step-wise increasing concentrations (GST-MycHisG, wt-CLSPCOL and CLSPCOL; concentrations 0.15-10nM), ×10ISF lysates and ×50 serum are shown in the Abs 450 column. Next, the average of the three values ​​is calculated, see the average Abs450 column. The Del average value is obtained by deducting the average value of the physiological saline from each average value. The Del GST values ​​for ×10 ISF lysates and ×50 serum were obtained by subtracting the average Del values ​​of GST-MycHisG (negative control) from the average Del values ​​of CLSPCOL or wt-CLSPCOL. Next, the concentrations of recombinant proteins in brain lysates containing ISF and serum were estimated using standard dose-response curves ( Figure 6 a).

[0324] Industrial Applicability

[0325] The CLSP derivatives, polypeptides, enhancers or protectors, and fusion proteins of the present invention can be used as pharmaceutical compositions for inhibiting neuronal dysfunction or neuronal cell death associated with Alzheimer's disease, for example, as active ingredients of pharmaceutical compositions for preventing or treating diseases accompanied by memory impairment or neurodegeneration associated with Alzheimer's disease.

[0326] Shown below is a list of documents cited in this specification.

[0327] [Citation list]

[0328] 1. Selkoe, DJ SnapShot: pathobiology of Alzheimer's disease. Cell 154, 468-468 (2013).

[0329] 2. Selkoe, DJ, & Hardy, J. The amyloid hypothesis of Alzheimer's disease at 25 years. EMBO Mol. Med. 8, 595-608. (2016).

[0330] 3.Scheltens,P.Alzheimer’s disease.Lancet,388,505-517(2016).

[0331] 4.Hashimoto,Y.,Kurita,M.,Aiso,S.,Nishimoto,I.,&Matsuoka,M.Humanininhibits neuronal cell death by interacting with a cytokine receptor complexor complexes involving CNTF receptor a / WSX-1 / gp130.Mol.Biol.Cell 20,2864-2873(2009).

[0332] 5.Hashimoto,Y.et al.Secreted calmodulin-like skin protein inhibitsneuronal death in cell-based Alzheimer’s disease models via theheterotrimeric Humanin receptor.Cell Death Dis.4:e555(2013).

[0333] 6.Matsuoka,M.Protective effects of Humanin and calmodulin-like skinprotein in Alzheimer’s disease andbroad range ofabnormalities.Mol.Neurobiol.51,1232-1239(2015).

[0334] 7.Matsuoka,M.HUMANIN:ADefender against Alzheimer’s disease.RecentPatents CNSDrug Discov.4,37-42(2009).

[0335] 8.Kusakari,S.,Nawa,M.,Sudo,K.,&Matsuoka,M.Calmodulin-like skinprotein protects against spatial learning impairment in a mouse model ofAlzheimer’s disease.J.Neurochem.144,218-233(2018).

[0336] 9.Widmer,R.J.et al.Circulating humanin levels are associated withpreserved coronary endothelial function.Am.J.Physiol.Heart Circ.Physiol.304,H393-7(2013).

[0337] 10.Mehul,B.,Bernard,D.,Simonetti,L.,Bernard,M.A.,&Schmidt,R.Identification and cloning ofa new calmodulin-like protein from humanepidermis.J.Biol.Chem.275,12841-12847(2000).11.Hwang,M.,&Morasso,M.I.Thenovel murine Ca2+-binding protein,Scarf,is differentially expressed duringepidermal differentiation.J.Biol.Chem.278,47827-47833(2003).

[0338] 12.Hwang,M.,Kalinin,A.,&Morasso,M.I.The temporal and spatialexpression of the novel Ca++-binding proteins,Scarf and Scarf2,duringdevelopment and epidermal differentiation.Gene Expr.Patterns 5,801-808(2005).

[0339] 13.Hayashi,M.,Tajima,H.,Hashimoto,Y.,&Matsuoka,M.Secreted calmodulin-like skin protein ameliorates scopolamine-induced memoryimpairment.Neuroreport 25,725-729(2014).

[0340] 14.Hashimoto,Y.,Umahara,T.,Hanyu,H.,Iwamoto,T.,&Matsuoka,M.Calmodulin-like skin protein is downregulated in human cerebrospinal fluidsof Alzheimer’s disease patients with apolipoprotein E4;a pilot study usingpostmortem samples.Neurol.Res.39,767-772(2017).

[0341] 15.Hwang,J.et al.Role of Scarfand its binding target proteins inepidermal calcium homeostasis.J.Biol.Chem.282,18645-18653(2007).

[0342] 16.Rebeck,G.W.The role of APOE on lipid homeostasis and inflammationin normal brains.J.Lipid Res.58,1493-1499(2017).

[0343] 17.Liao,F.,Yoon,H.,&Kim,J.Apolipoprotein E metabolism and functionsin brain and its role in Alzheimer’s disease.Curr.Opin.Lipidol.28,60-67(2017)

[0344] 18.Lindh,M.et al.Cerebrospinal fluid apolipoprotein E(apoE)levels inAlzheimer’s disease patients are increased at follow up and show acorrelation with levels oftau protein.Neurosci Lett.229,85-88(1997).

[0345] 19.Schmidt,C.et al.Cerebrospinal fluid apolipoprotein E concentrationand progression of Alzheimer’s disease.J.Alzheimers Dis.43,1229-1236(2015).

[0346] 20.Wahrle,S.E.et al.Apolipoprotein E levels in cerebrospinal fluidand the effects of ABCA1polymorphisms Mol.Neurodegener.2,7(2007).

[0347] 21.Matsui,Y.et al.High sensitivity ofan ELISA kit for detection ofthegamma-isoform of 14-3-3proteins:usefulness in laboratory diagnosis ofhumanprion disease.BMC Neurol.11,120(2011).22.Liu,R.et al.Calreticulin as apotential diagnostic biomarker for lung cancer.Cancer Immunol.Immunother.61,855-864(2012).

[0348] 23.Liu,M.,&Liu,F.Transcriptional and post-translational regulation ofadiponectin Biochem.J.425,41-52(2010).

[0349] 24.Takeshita,Y.,Hashimoto,Y.,Nawa,M.,Uchino,H.&Matsuoka,M.SH3-bindingprotein 5mediates the neuroprotective effect of the secreted bioactivepeptide humanin by inhibiting c-Jun NH2-terminal kinase.J.Biol.Chem.288,24691-24704(2013).

[0350] 25.Niikura,T.,Sidahmed,E.,Hirata-Fukae,C.,Aisen,P.S.,Matsuoka,Y.Ahumanin derivative reduces amyloid beta accumulation and ameliorates memorydeficit in triple transgenic mice.PloS one 6:e16259(2011).

[0351] 26.Zhang,W.et al.S14G-humanin improves cognitive deficits and reducesamyloid pathology in the middle-agedAPPswe / PS1dE9mice.Pharmacol.Biochem.Behavior 100,361-369.(2012).

[0352] 27.Yin,R.et al.Protective Effects ofColivelin Against Alzheimer’sDisease in a PDAPP Mouse Model.Cell.physiol.Biochem.38,1138-1146(2016).

[0353] 28.Combs T.P.,Berg A.H.,Obici S.,Scherer P.E.,&Rossetti L.Endogenousglucose production is inhibited by the adipose-derivedproteinAcrp30.J.Clin.Investig.108,1875-1881(2001).

[0354] 29.Une,K.et al.Adiponectin in plasma and cerebrospinal fluid in MCIand Alzheimer’s disease.Eur.J.Neurol.18,1006-1009(2011).

[0355] 30.Waragai,M.et al.Possible Involvement of Adiponectin,the Anti-Diabetes Molecule,in the Pathogenesis ofAlzheimer’s Disease.J.AlzheimersDis.52,1453-9(2016).

[0356] 31.Ng,R.C.,&Chan,K.H.Potential Neuroprotective Effects of Adiponectinin Alzheimer’s Disease.Int.J.Mol.Sci.18,pii:E592(2017).

[0357] 32.Himbergen,T.M.V.et al.Biomarkers for Insulin Resistance andInflammation and the Risk for All-Cause Dementia and Alzheimer DiseaseResults From the Framingham Heart Study.Arch.Neurol.69,564-600(2012).

[0358] 33.Garcia-Casares N.et al.Alzheimer’s like brain changes correlatewith low adiponectin plasma levels in type 2 diabetic patients.J.DiabetesComplicat.30,281-286(2016).

[0359] 34.Ng,R.C.L.et al.Chronic adiponectin deficiency leads to Alzheimer’sdisease-like cognitive impairments through AMPK inactivation and cerebralinsulin resistance in aged mice.Mol.Neurodegener.11,71(2016).

[0360] 35.Chiba,T.et al.Amyloid-beta causes memory impairment by disturbingthe JAK2 / STAT3 axis in hippocampal neurons.Mol.Psychiatry 14,206-222(2009).

[0361] 36.Liu,X.et al.Unbound drug concentration in brain homogenate andcerebral spinal fluid at steady state as a surrogate for unboundconcentration in brain interstitial fluid.Drug Metab.Dispos.37,787-93(2009).

[0362] 37.Sweeney,M.D.,Sagare,A.P.,&Zlokovic,B.V.Blood-brain barrierbreakdown in Alzheimer disease and other neurodegenerativedisorders.Nat.Rev.Neurol.14,133-150(2018).

[0363] 38. Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. Apolipoprotein E and Alzheimerdisease: risk, mechanisms, and therapy Nat. Rev. Neurol. 9, 106-118 (2012).

[0364] 39. Yamatsuji, T., et al. G protein-mediated neuronal DNA fragmentation induced by familial Alzheimer's disease-associated mutants of APP. Science 272, 1349-1352 (1996).

[0365] 40. Mirra, SS et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41, 479-486 (1999).

[0366] 41. Braak H., & Braak E. Neuropathological staging of Alzheimer-related changes. Acta Neuropathol (Berl) 82, 239-59 (1991).

[0367] 42. Pajvani, U et al. Structure-function studies of the adipocyte-secreted hormone Acrp30 / adiponectin. Implications for metabolic regulation and bioactivity J. Biol. Chem. 278, 9073 (2003). <110> Tokyo Medical University <120> CLSP derivatives not affected by CLSP-inhibiting substances and enhancers / protectants for CLSP activity <130> PCT-AB20018 <150> JP 2019-149216 <151> 2019-08-15 <160> 11 <170> PatentIn version 3.5 <210> 1 <211> 146 <212> PRT <213> Human <220> <223> CLSP <400> 1 Met Ala Gly Glu Leu Thr Pro Glu Glu Glu Ala Gln Tyr Lys Lys Ala 1 5 10 15 Phe Ser Ala Val Asp Thr Asp Gly Asn Gly Thr Ile Asn Ala Gln Glu 20 25 30 Leu Gly Ala Ala Leu Lys Ala Thr Gly Lys Asn Leu Ser Glu Ala Gln 35 40 45 Leu Arg Lys Leu Ile Ser Glu Val Asp Ser Asp Gly Asp Gly Glu Ile 50 55 60 Ser Phe Gln Glu Phe Leu Thr Ala Ala Lys Lys Ala Arg Ala Gly Leu 65 70 75 80 Glu Asp Leu Gln Val Ala Phe Arg Ala Phe Asp Gln Asp Gly Asp Gly 85 90 95 His Ile Thr Val Asp Glu Leu Arg Arg Ala Met Ala Gly Leu Gly Gln 100 105 110 Pro Leu Pro Gln Glu Glu Leu Asp Ala Met Ile Arg Glu Ala Asp Val 115 120 125 Asp Gln Asp Gly Arg Val Asn Tyr Glu Glu Phe Ala Arg Met Leu Ala 130 135 140 Gln Glu 145 <210> 2 <211> 60 <212> PRT <213> Artificial Sequence <220> <223> ADNCol <400> 2 Gly His Pro Gly His Asn Gly Ala Pro Gly Arg Asp Gly Arg Asp Gly 1 5 10 15 Thr Pro Gly Glu Lys Gly Glu Lys Gly Asp Pro Gly Leu Ile Gly Pro 20 25 30 Lys Gly Asp Ile Gly Glu Thr Gly Val Pro Gly Ala Glu Gly Pro Arg 35 40 45 Gly Phe Pro Gly Ile Gln Gly Arg Lys Gly Glu Pro 50 55 60 <210> 3 <211> 244 <212> PRT <213> Human <220> <223> Adiponectin (ADN) <400> 3 Met Leu Leu Leu Gly Ala Val Leu Leu Leu Leu Ala Leu Pro Gly His 1 5 10 15 Asp Gln Glu Thr Thr Thr Gln Gly Pro Gly Val Leu Leu Pro Leu Pro 20 25 30 Lys Gly Ala Cys Thr Gly Trp Met Ala Gly Ile Pro Gly His Pro Gly 35 40 45 His Asn Gly Ala Pro Gly Arg Asp Gly Arg Asp Gly Thr Pro Gly Glu 50 55 60 Lys Gly Glu Lys Gly Asp Pro Gly Leu Ile Gly Pro Lys Gly Asp Ile 65 70 75 80 Gly Glu Thr Gly Val Pro Gly Ala Glu Gly Pro Arg Gly Phe Pro Gly 85 90 95 Ile Gln Gly Arg Lys Gly Glu Pro Gly Glu Gly Ala Tyr Val Tyr Arg 100 105 110 Ser Ala Phe Ser Val Gly Leu Glu Thr Tyr Val Thr Ile Pro Asn Met 115 120 125 Pro Ile Arg Phe Thr Lys Ile Phe Tyr Asn Gln Gln Asn His Tyr Asp 130 135 140 Gly Ser Thr Gly Lys Phe His Cys Asn Ile Pro Gly Leu Tyr Tyr Phe 145 150 155 160 Ala Tyr His Ile Thr Val Tyr Met Lys Asp Val Lys Val Ser Leu Phe 165 170 175 Lys Lys Asp Lys Ala Met Leu Phe Thr Tyr Asp Gln Tyr Gln Glu Asn 180 185 190 Asn Val Asp Gln Ala Ser Gly Ser Val Leu Leu His Leu Glu Val Gly 195 200 205 Asp Gln Val Trp Leu Gln Val Tyr Gly Glu Gly Glu Arg Asn Gly Leu 210 215 220 Tyr Ala Asp Asn Asp Asn Asp Ser Thr Phe Thr Gly Phe Leu Leu Tyr 225 230 235 240 His Asp Thr Asn <210> 4 <211> 48 <212> DNA <213> Artificial sequence <220> <223> HiBit uses the justice sequence <400> 4 cccggggtga gcggctggcg gctgttcaag aagattagct gagaattc 48 <210> 5 <211> 48 <212> DNA <213> Artificial sequence <220> <223> HiBit uses antisense sequences <400> 5 cccggggtga gcggctggcg gctgttcaag aagattagct gagaattc 48 <210> 6 <211> 43 <212> DNA <213> Artificial sequence <220> <223> Sense Primer <400> 6 ggttgagaat tcatcgtgac tgactgacga tctgcctcgc gcg 43 <210> 7 <211> 42 <212> DNA <213> Artificial sequence <220> <223> Antisense primer <400> 7 atgatgatga tgatgatgat cctcttctgagatgagtttt tg 42 <210> 8 <211> 42 <212> DNA <213> Artificial sequence <220> <223> Sense Primer <400> 8 ggatccatga gaggatcgca tcaccatcac catcacgggt cc 42 <210> 9 <211> 44 <212> DNA <213> Artificial sequence <220> <223> Antisense primer <400> 9 gaattctcaa ggttctcctt tcctgccttg gattccccgga aagc 44 <210> 10 <211> 88 <212> DNA <213> Artificial sequence <220> <223> Sense Primer <400> 10 aagcttgaac aaaaactcat ctcagaagag gatcatcatc atcatcatca tggtatgggg 60 catccgggcc ataatggggccccaggcc 88 <210> 11 <211> 45 <212> DNA <213> Artificial sequence <220> <223> Antisense primer <400> 11 gaattctcaa ggttctcctt tcctgccttg gattccccgga aagcc 45< / f>

Claims

1. A non-therapeutic use of a polypeptide as an enhancer or protector of calmodulin-like skin protein (CLSP) activity, wherein: The polypeptide consists of the following amino acid sequence: (1) the amino acid sequence ADNCol shown in SEQ ID NO: 2; or (2) an amino acid sequence of adiponectin shown in SEQ ID NO: 3 comprising the amino acid sequence ADNCol of (1) above, The present invention does not contain a region to which the inhibitor of CLSP activity binds, and the inhibitor of CLSP activity is selected from the group consisting of apolipoprotein E, 14-3-3 protein and calreticulin.

2. The use according to claim 1, wherein: The region to which the inhibitor binds is amino acids 62 to 146 of the C-terminal region of CLSP SEQ ID NO:

1.

3. The use according to claim 1, characterized in that: The CLSP is protected from the inhibitory or suppressive effect of the inhibitor on the activity of the CLSP, or the inhibitory effect is ineffective.

4. The use according to any one of claims 1 to 3, wherein The above polypeptide is adiponectin.

5. A fusion protein comprising calmodulin-like skin protein (CLSP) and the following polypeptide, wherein: The polypeptide consists of the following amino acid sequence: (1) the amino acid sequence ADNCol shown in SEQ ID NO: 2; or (2) an amino acid sequence of adiponectin shown in SEQ ID NO: 3 comprising the amino acid sequence ADNCol of (1) above, The present invention does not contain a region to which the inhibitor of CLSP activity binds, and the inhibitor of CLSP activity is selected from the group consisting of apolipoprotein E, 14-3-3 protein and calreticulin.

6. The fusion protein according to claim 5, wherein The region to which the inhibitor binds is amino acids 62 to 146 of the C-terminal region of CLSP SEQ ID NO:

1.

7. The fusion protein according to claim 5, which is composed of amino acids 1 to 61 of the N-terminal region of CLSP and ADNCol.

8. The fusion protein according to any one of claims 5 to 7, which is not inhibited or suppressed by an inhibitor on CLSP activity. 9 . A pharmaceutical composition comprising the fusion protein according to claim 5 as an active ingredient.

10. Use of the fusion protein according to any one of claims 5 to 8 for the preparation of a medicament for a disease accompanied by neuronal cell dysfunction or neuronal cell death, or a disease accompanied by memory impairment or neurodegeneration.

11. The use according to claim 10, wherein: The disease or condition is Alzheimer's disease.

12. A method for screening a substance that modulates the inhibitory activity of the fusion protein according to any one of claims 5 to 8 on neuronal dysfunction or neuronal cell death associated with Alzheimer's disease, the method comprising: Step (a), inducing neuronal dysfunction or neuronal cell death in the presence of a fusion protein and in the presence or absence of a test substance; Step (b) of detecting neuronal dysfunction or neuronal cell death; and step (c) of selecting a substance that modulates the inhibitory activity of the fusion protein on neuronal dysfunction or neuronal cell death.